UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



FORM 10
– K/A

(Amendment No. 1)



ANNUAL REPORT PURSUANT TO SECTION 13 OR
15 (d)

OF THE SECURITIES EXCHANGE ACT OF 1934



For the fiscal year ended June 30, 2018



Commission file number 000-04217



ACETO
CORPORATION(Exact name of registrant as specified in its charter)



|New York                                                        |  | 11-1720520                              
|--------------------------------------------------------------- |  | ----------------------------------------
|(State or other jurisdiction of 
incorporation or organization) |  | (I.R.S. Employer 
Identification Number)



|                                         | 4 Tri Harbor Court, Port
    Washington, NY 11050 | 
|---------------------------------------- | ------------------------------------------------- | 
|(Address of principal executive offices)



(516) 627-6000

(Registrant's telephone number, including
area code)



Securities registered pursuant to Section 12 (b) of the Act:



|Common Stock, par value $.01 per share |  | The NASDAQ Global Select Market            
|-------------------------------------- |  | -------------------------------------------
|(Title of Class)                       |  | (Name of each exchange on which registered)



Securities registered pursuant to Section
12 (g) of the Act: None



Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes  ̈
No x



Indicate by check mark if the registrant
is not required to file reports pursuant to Section 13 of Section 15(d) of the Act.

Yes  ̈
No x



Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes x No  ̈



Indicate by check mark whether the
registrant has submitted electronically, every interactive data file required to
be submitted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit such files). Yes x
No  ̈



Indicate by check mark if disclosure of
delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the
Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or
any amendment to this Form 10-K.  ̈



Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act. (Check one):



|Large accelerated filer  ̈ | Accelerated filer x        
|------------------------- | ---------------------------
|                          |                            
|Non-accelerated filer  ̈   | Smaller reporting company  ̈



Emerging growth company  ̈



If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ̈



Indicate by check mark whether the Registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  ̈
No x



The aggregate market value of the voting
stock of the Company held by non-affiliates of the Company based on the
closing price of the common stock on December 29, 2017 as reported on the NASDAQ Global Select Market was approximately
$267,428,195.



The Registrant has 30,800,574 shares of
common stock outstanding as of October 15, 2018.



Documents incorporated by reference:



None


















Explanatory Note



This Amendment No. 1 on Form 10-K/A (this
“Amendment”) amends our Annual Report on Form 10-K for the fiscal year ended June 30, 2018 (Commission File Number
000-04217), originally filed on September 28, 2018 (the “Original Filing”). We are filing this Amendment to include
the information required by Part III and not included in the Original Filing, as we do not intend to file a definitive proxy statement
for an annual general meeting of stockholders within 120 days of the end of our fiscal year ended June 30, 2018. In addition,
in connection with the filing of this Amendment and pursuant to the rules of the Securities and Exchange Commission (the “SEC”),
we are including with this Amendment new certifications of our principal executive officer and principal financial officer pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002. Item 15 of Part IV has been amended to reflect the filing of these new
certifications, to reflect the filing of compensatory agreements relating to an individual who has become a named executive officer
for the first time and to reflect a template agreement associated with a compensatory arrangement described in Item 11.



Except as described above, no other changes
have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and we have
not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original
Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing and our other filings with the SEC.



As used in this Amendment, unless the context
requires otherwise, the “Company”, “Aceto”, “our” and “we” refers to Aceto Corporation,
Inc. and its consolidated subsidiaries, and U.S. GAAP means accounting principles generally accepted in the United States of America.



2







TABLE OF CONTENTS



|PART III.  |                                                                                                |   
|---------- | ---------------------------------------------------------------------------------------------- | --
|Item 10.   | Directors, Executive Officers and Corporate Governance                                         | 4 
|Item 11.   | Executive Compensation                                                                         | 12
|Item 12.   | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 30
|Item 13.   | Certain Relationships and Related Transactions and Director Independence                       | 32
|Item 14.   | Principal Accounting Fees and Services                                                         | 32
|           |                                                                                                |   
|PART IV.   |                                                                                                |   
|Item 15.   | Exhibits and Financial Statement Schedules                                                     | 33
|           |                                                                                                |   
|SIGNATURES |                                                                                                | 39



3







PART III



Item 10. Directors, Executive Officers
and Corporate Governance



DIRECTORS



The names of the directors, their ages
(as of October 15, 2018), their committee positions and the period during which they have been serving on our Board of Directors
(the “Board”) are set forth in the table below:



|NAME                     |  | AGE |  | AUDIT & RISKCOMMITTEE |  | COMPENSATIONCOMMITTEE |  | NOMINATING &GOVERNANCECOMMITTEE |  | DIRECTORSINCE
|------------------------ |  | --- |  | --------------------- |  | --------------------- |  | ------------------------------- |  | -------------
|                         |  |     |  |                       |  |                       |  |                                 |  |              
|Alan G. Levin (1)        |  | 56  |  | X                     |  | X                     |  | X                               |  | 2013         
|William C. Kennally, III |  | 62  |  |                       |  |                       |  |                                 |  | 2016         
|Albert L. Eilender       |  | 75  |  |                       |  |                       |  |                                 |  | 2000         
|Vimal Kavuru             |  | 50  |  |                       |  |                       |  |                                 |  | 2017         
|William N. Britton       |  | 73  |  | C                     |  |                       |  | X                               |  | 2006         
|Natasha Giordano         |  | 58  |  | X                     |  | C                     |  |                                 |  | 2011         
|Dr. Daniel B. Yarosh     |  | 64  |  |                       |  | X                     |  | C                               |  | 2014         



(1) Chairman of the Board

C – Chairperson

X – Committee member



No director or executive
officer of the Company is related to any other director or executive officer. None of the Company’s officers or directors
holds any directorships in any other public company, except for Mr. Levin, who is a member of the board of directors of Diffusion
Pharmaceuticals, Inc., and Natasha Giordano, who is a member of the board of directors (and the president and chief executive officer)
of PLx Pharma Inc. A majority of our board members are independent based on the definition of independence in Listing Rule 5605(a)(2)
of The NASDAQ Stock Market.



Set forth below is
the business experience of, and any other public company or registered investment company directorships held by, the members of
the Board for at least the past five years, as well as a summary of their specific experience, qualifications, attributes or skills
that led the Board to conclude that they should serve as our directors.



Biographies of Current Directors



Alan G. Levin. Mr. Levin was elected
Non-Executive Chairman of the Board as of July 2018. He joined the Aceto Board in December 2013 and became Lead Independent Director
in July 2016. Prior to joining the Aceto Board, Mr. Levin served as Executive Vice President and Chief Financial Officer of Endo
Health Solutions Inc. (Endo), a global specialty healthcare company, from June 2009 until September 2013. Prior to joining Endo,
Mr. Levin worked with Texas Pacific Group, a leading private equity firm, and one of their start-up investments. Before that, he
was Senior Vice President & Chief Financial Officer of Pfizer, Inc. where he worked for 20 years in a variety of executive
positions of increasing responsibility, including Treasurer and Senior Vice President of Finance & Strategic Management for
the company’s research and development organization. Mr. Levin received a bachelor’s degree from Princeton University
and a master’s degree from New York University’s Stern School of Business. Mr. Levin is a certified public accountant.
He is a member of the Advisory Board of Auven Therapeutics, a private equity fund, a member of the Board of Directors of Diffusion
Pharmaceuticals Inc., a development stage oncology company, and a member of the Board of Directors of the Critical Path Institute,
a non-profit collaboration between the Food and Drug Administration and pharmaceutical industry participants. We believe that Mr.
Levin’s financial experience, including his prior positions as chief financial officer of Endo and Pfizer and executive-level
experience in the pharmaceutical industry, as well as his experience in financial reporting, treasury and corporate finance, gives
him the qualifications and skills to serve as one of our directors.



4







William C. Kennally, III. For information
regarding Mr. Kennally, see “—Executive Officers.” Mr. Kennally’s leadership position in our Company, together
with his experience managing both brand and generic pharmaceutical businesses, gives him the qualifications and skills to serve
as one of our directors.



Albert L. Eilender. Mr. Eilender
was named Chairman Emeritus in July 2018 after serving as the Chairman of the Board since October 2009. He joined the Board in
2000, was the lead independent director from 2005 to September 2009 and served as Chief Executive Officer of the Company from September
2010 to January 2013. He is the sole owner of Waterways Advisory Services, a firm specializing in advising companies on developing
and evaluating options relative to mergers, acquisitions and strategic partnerships in the chemical industry. Mr. Eilender has
not been active in the operations of this enterprise since October 2009. He has more than 35 years of diverse senior level experience
in the specialty chemicals and pharmaceutical industry and has had direct financial responsibility, with significant experience
in mergers, acquisitions and joint ventures, both domestically and internationally. He has also served on the boards of numerous
industry trade associations during his career. We believe that Mr. Eilender’s past 25 years of industry experience in executive
management for operations within all three segments of Aceto’s business, as well as operations in North America, Europe and
Asia, coupled with his experience in the areas of business consultation and mergers and acquisitions, and his service on the Board
since 2000, give him the qualifications and skills to serve as one of our directors.



Vimal Kavuru. Since 2013, Mr. Kavuru
has been the CEO of Cedar Pharma LLC (formerly known as Citron Pharma LLC) and Aster Pharma LLC (formerly known as Lucid Pharma
LLC), from which Rising acquired certain generic products and related assets in December 2016. Cedar and Aster provide certain
transition services to Rising. In 2008, Mr. Kavuru founded and served as CEO until 2013 of Gen-Source RX, a generic pharmaceutical
distributor that was sold to Cardinal Health in 2014. Since 2007, Mr. Kavuru has served as a director of Celon Labs Ltd., an Indian
specialty pharmaceutical company focused on the oncology and critical care segments. Additionally, he has served as a director
of Cronus Pharma LLC, an animal health pharmaceutical company, since 2016, is the founder of Casper Pharma LLC, an emerging specialty
brand and injectable pharmaceutical company, and is a co-founder of Grace Therapeutics, a specialty pharmaceutical company focused
on treating rare and orphan diseases. Mr. Kavuru graduated with a B.S. in Pharmacy from the College of Pharmacy, Gulbarga, India
and is a registered Pharmacist in the State of New York. We believe that Mr. Kavuru’s extensive experience in the generic
products industry, as well as his previous association with Citron and Lucid gives him the qualifications and skills to serve as
one of our directors.



William N. Britton. Mr. Britton
is the sole owner of TD AIM, LLC, through which he is involved in a variety of activities surrounding financial consulting and
private equity investing. Mr. Britton is also a Vice Chairman of P and E Capital, Inc., a management company involved in real estate.
Previously, Mr. Britton was a Senior Vice President with JP Morgan Chase. He has over 30 years of commercial lending experience
ranging from large syndicated financings with Fortune 500 companies to privately owned businesses, with significant experience
in private equity related transactions, asset based lending arrangements, leasing and many other forms of secured lending. Mr.
Britton is a former member of the Northeast Advisory Council of Opera Solutions, a private firm engaged in consulting. Mr. Britton
is a former Vice President-Finance for the Boy Scouts of America (Manhattan Council) and is on the board of the Rutgers Business
School. We believe that Mr. Britton’s finance and business consultation and executive-level management experience, as well
as his service on the Board of the Company since 2006, give him the qualifications and skills to serve as one of our directors.



Natasha Giordano. Ms. Giordano has
been the President and Chief Executive Officer as well as a Director of PLx Pharma Inc. since January 2016. PLx Pharma is a
late-stage specialty pharmaceutical company focused on developing a clinically validated and patent protected delivery system to
provide more effective and safer aspirin products. Previously, Ms. Giordano served as the Chief Executive Officer of ClearPoint
Learning, Inc., from May 2015 through November 2015 and a director of ClearPoint from December 2009 through November 2015. Prior
to ClearPoint, Ms. Giordano served as the Chief Executive Officer of Healthcare Corporation of America from January 2014 through
August 2014. From 2009 to August 2012, Ms. Giordano served as Chief Operating Officer and then Chief Executive Officer and President
of Xanodyne Pharmaceuticals, Inc., a branded specialty pharmaceutical company with development and commercial capabilities focused
on pain management and women’s health. From 2000 to 2008, she served in various senior management positions at Cegedim Dendrite
(formerly Dendrite International Inc.), including serving as President, Americas from 2007 to 2008. Earlier in her career, Ms.
Giordano worked for nine years at Parke-Davis, a subsidiary of Warner Lambert. Ms. Giordano holds a Bachelor of Science degree
in nursing from Wagner College. We believe that Ms. Giordano’s twenty plus years of senior leadership positions in the healthcare
and pharmaceutical industry brings to our Board a vast amount of practical experience in general management, strategy, marketing,
sales development, and compliance, which give her the qualifications and skills to serve as one of our directors.



5







Daniel B. Yarosh, PhD. Daniel B.
Yarosh, PhD is the former Chief Technology Advisor, Estee Lauder Companies, a manufacturer and marketer of skin care, makeup, fragrance
and hair care products, from 2014 to 2017. From 2008 to 2014 he was Senior Vice President of Basic Science Research at Estee Lauder
R&D. He founded and served as President and Chairman of Applied Genetics Inc. Dermatics, a biotech company focusing on DNA
science for 23 years before selling it to Estee Lauder. Dr. Yarosh has a PhD degree in molecular biology, and was a National Science
Foundation postdoctoral fellow at Brookhaven National Laboratories and Staff Fellow and Cancer Expert at the National Cancer Institute,
National Institutes of Health in Bethesda, Maryland. He is active in the New York biotech community and many scientific and medical
societies, including the American Academy of Dermatology. Dr. Yarosh is the author of over 100 scientific papers, two dozen patents,
and the book “The New Science of Perfect Skin”. Dr. Yarosh is a volunteer board member of the Photomedicine Society,
a medical professional non-profit society and is also a volunteer advisor to other professional scientific, medical and patient
groups. Dr. Yarosh received a bachelor’s degree in biology from Macalester College and a PhD from the University of Arizona
School of Medicine. Dr. Yarosh’s prior experience, including his executive and scientific research experience at Estee Lauder
and his expertise in the biotech industry, gives him the qualifications and skills to serve as one of our directors.



INFORMATION ABOUT THE COMPANY’S
COMMITTEES



Audit & Risk Committee



The Audit & Risk Committee is currently comprised of William N. Britton (Chairman), Alan G. Levin and Natasha Giordano. 	The Audit
& Risk Committee recommends to the Board the approval of the Company’s independent registered public accounting firm
and reviews management actions in matters relating to audit functions. The committee reviews with the Company’s independent
registered public accounting firm the scope and results of its audit engagement and the Company’s system of internal controls
and procedures. The committee also reviews the effectiveness of procedures intended to prevent violations of laws. The committee
also reviews, prior to publication, our quarterly earnings releases and reports to the SEC on Form 10-K and Form 10-Q.



The
Audit & Risk Committee has adopted a written policy for the pre-approval of audit, audit-related and non-audit
services to be provided by the Company’s independent registered public accounting firm. In general, the Company’s
independent registered public accounting firm cannot be engaged to provide any audit or non-audit services unless the
engagement is pre-approved by the Audit & Risk Committee in compliance with the Sarbanes-Oxley Act of 2002. Certain basic
services may also be pre-approved by the Chairman of the Audit & Risk Committee under the policy.



The
Audit & Risk Committee, consistent with the Sarbanes-Oxley Act of 2002 and the rules adopted thereunder, also
meets with management and the auditors prior to the filing of officers’ certifications with the SEC to request
information concerning, among other things, significant deficiencies in the design or operation of internal controls, if
any.



The Audit & Risk
Committee assists the Board in performing its oversight responsibilities relating to the Company’s processes and
policies with respect to identifying, monitoring, assessing, reporting on, managing and controlling the Company’s
business and financial risk. The Audit & Risk Committee discusses with the Company’s Senior Risk Officer, and other
members of management responsible for managing risk, areas of specific risk identified by management and/or the
Committee.



The Board has determined that all Audit
& Risk Committee members are independent under applicable SEC regulations, and based on the definition of independence in
Listing Rule 5605(a)(2) of The NASDAQ Stock Market. Our Board has determined that Mr. Britton and Mr. Levin qualify as an “audit
committee financial expert” as that term is used in SEC regulations. The Audit & Risk Committee operates under a formal
charter that governs its duties and conduct and is published on the Company’s corporate website – www.aceto.com.



The Audit & Risk
Committee has adopted a Non-Retaliation Policy and a Complaint Monitoring Procedure to enable confidential and anonymous reporting
regarding financial irregularities, if any.



6







Nominating and Governance Committee



The Nominating and Governance Committee
is currently comprised of Alan G. Levin, William N. Britton and Dr. Daniel B. Yarosh (Chairperson), each of whom has been determined
by the Board to be an “independent director” based on the definition of independence in Listing Rule 5605(a)(2) of
The NASDAQ Stock Market. The Nominating and Governance Committee addresses Board organizational issues and reviews the Company’s
corporate governance framework. In addition, the Nominating and Governance Committee searches for persons qualified to serve on
the Board and monitors, assesses and makes recommendations to the Board annually with respect to the leadership structure of the
Board. While the Nominating and Governance Committee does not have a formal policy on diversity for members of the Board, the Nominating
and Governance Committee considers diversity of background, experience and qualifications in evaluating prospective Board members.
The committee will evaluate the suitability of potential nominees for membership on the Board, taking into consideration the Board’s
current composition, including expertise, diversity, and balance of inside, outside and independent directors, and considering
the qualifications and criteria established by the Board. In considering director candidates, the Nominating and Governance Committee
and the Board endeavor to establish a diversity of background and experience in a number of areas of core competency, including
business judgment, management, accounting and finance, knowledge of the industries in which the Company operates, strategic vision,
knowledge of international markets, and other areas relevant to the Company’s business.



The Nominating and Governance Committee
operates under a formal charter that governs its duties and conduct and is published on the Company’s corporate website
– www.aceto.com.



The Company’s By-laws contain provisions
which address the process by which a shareholder may nominate an individual to stand for election to the Board at the Company’s
annual meeting of shareholders. The Nominating and Governance Committee will consider and vote on any recommendations so submitted.
In considering any person recommended by a shareholder, the committee will look for the same qualifications that it looks for in
any other person that is considered for a position on the Board.



Any shareholder nominee recommended by
the Nominating and Governance Committee and proposed by the Board for election at the next annual meeting of shareholders will
be included in the company's proxy statement for that annual meeting.



Director Resignation Policy



The Company has
established a “Director Resignation Policy”, which addresses the situation in which a nominee for election to the
Company’s Board fails to receive a majority of the votes cast by the shareholders of the Company in an uncontested election
of directors. An “uncontested election of directors” is any election of directors by the shareholders of the Company
in which the number of nominees for election does not exceed the number of directors to be elected. Pursuant to our Director Resignation
Policy, if, in any uncontested election, a nominee receives less than a majority of the votes cast by the shareholders of the
Company, such nominee is required to promptly tender his or her written resignation from the Board to the Secretary of the Company.
The Board will then determine whether to accept or reject the resignation. The Director Resignation Policy is published on the
Company’s corporate website – www.aceto.com.



Compensation
Committee



The Compensation
Committee is currently comprised of Natasha Giordano (Chairperson), Alan Levin and Dr. Daniel B. Yarosh, each of whom has been
determined by the Board to be an “independent director” based on the definition of independence in Listing Rule 5605(a)(2)
of The NASDAQ Stock Market. The Compensation Committee conducts reviews of the compensation of the directors, Chief Executive Officer
and other senior executive officers of the Company including evaluating and making recommendations to the Board concerning those
officers’ benefits, bonus, incentive compensation, severance, equity-based compensation, and other forms of compensation
provided by the Company. The Compensation Committee meets as it determines to be necessary, but not less frequently than annually.
The Compensation Committee may delegate a portion of its authority to a subcommittee or subcommittees. The Compensation Committee
has the exclusive authority to retain any compensation consultants to be used to assist the committee in the evaluation and determination
of the Company’s compensation for its Chief Executive Officer, other senior executive officers and directors.



The Compensation
Committee operates under a formal charter that governs its duties and conduct and reviews the charter not less than every two
years. The charter is published on the Company’s corporate website – www.aceto.com.



7







Compensation Consultant Role



Our Compensation Committee engaged Frederic
W. Cook & Co. Inc. (FW Cook), an executive compensation consulting firm, during the fiscal year ended June 30, 2018 to conduct
compensation benchmarking for our executive officers, as well as Board compensation analysis and a review of competitive severance
opportunities. In addition, the Compensation Committee utilized FW Cook to review our peer group composition. Our Compensation
Committee directed FW Cook to provide it with the benefits of its industry experience after taking into account the specific needs
and positioning of our Company. The Compensation Committee intends to continue to engage a compensation consulting firm to perform
executive and director compensation studies as needed.



While FW Cook provided data and advice
regarding our compensation practices, our Compensation Committee exercises autonomy when formulating and presenting recommendations
to our Board regarding our compensation practices for our named executive officers and Board of Directors. Our Compensation Committee
has assessed FW Cook’s independence pursuant to applicable SEC rules and concluded that no conflict of interest exists that
would prevent FW Cook from independently advising the Compensation Committee.



Management’s Role in Establishing
Our Executive Compensation



Our Chief Executive Officer plays an important
role in assisting our Compensation Committee in establishing the compensation for our executive officers. Key aspects of this role
include:



• suggesting to the Compensation Committee
business performance targets and objectives;



• evaluating employee performance; and



• recommending salary and bonus levels and
long-term incentive compensation.



During this process, the Compensation Committee
may ask our Chief Executive Officer, Chairman of the Board and other executive officers to provide guidance to the Compensation
Committee regarding background information for our strategic objectives, an evaluation of the performance of our executive officers,
and compensation recommendations as to the executive officers. Members of the Compensation Committee met informally with our Chief
Executive Officer and Chairman of the Board throughout the year to discuss compensation matters and compensation policies in order
to obtain insight regarding the day-to-day performance of each of our executive officers.



Board and Committee Meetings



During the Company’s fiscal year
ended June 30, 2018, the Board held ten meetings and acted by unanimous written consent one time. Each director attended at least
75% of the Board’s meetings and the meetings of the Board committees on which he or she served.



At most scheduled meetings of the Board,
the independent members of the Board met separately in executive session without management being present.



During the Company’s fiscal year
ended June 30, 2018, the Compensation Committee met eight times, the Audit & Risk Committee met eight times and the Nominating
and Governance Committee met four times.



Director Attendance at Annual Meetings



Our directors are encouraged, but not required,
to attend the annual meeting of shareholders. All of our directors attended the 2017 annual meeting of shareholders.



Communications by our Shareholders
to the Board



The Board recommends that shareholders
direct to the Company’s secretary any communications intended for the Board. Shareholders can send communications by e-mail
to srogers@aceto.com, by facsimile to (516) 627-6093, or by mail to Steven Rogers, Senior Vice President, Chief Legal Officer and
Secretary, Aceto Corporation, 4 Tri Harbor Court, Port Washington, New York 11050.



This centralized process will assist the
Board in reviewing and responding to shareholder communications in an appropriate manner. If a shareholder wishes to direct any
communication to a specific board member, the name of that board member should be noted in the communication. The Board has instructed
the Secretary to forward shareholder correspondence only to the intended recipients, but the Board has also instructed the Secretary
to review all shareholder correspondence and, in his discretion, not forward any items that he deems to be of a commercial or
frivolous nature or otherwise inappropriate for the Board's consideration. Any such items may be forwarded elsewhere in the Company
for review and possible response. The Company has adopted a Non-Retaliation Policy, or a whistleblower policy, which establishes
procedures for submitting these types of concerns, either personally or anonymously through a toll free telephone “hotline”
operated by an independent party. A copy of our Non-Retaliation Policy is available on our website at www.aceto.com.



8







CORPORATE GOVERNANCE



The Company operates within a comprehensive
plan of corporate governance for the purpose of defining responsibilities, setting high standards of professional and personal
conduct and assuring compliance with those responsibilities and standards. In July 2002, Congress passed the Sarbanes-Oxley Act
of 2002 which, among other things, establishes, or provides the basis for, a number of corporate governance standards and disclosure
requirements. In addition, the NASDAQ Stock Market has corporate governance and listing requirements. The Company also has policies
covering non-discrimination and diversity that are communicated to all employees. The Board has initiated numerous actions consistent
with these rules and will continue to monitor developments in the area of corporate governance regularly.



Code of Business Conduct and Ethics



The Company has adopted a Code of Business
Conduct and Ethics for all Aceto directors, officers and employees that includes provisions ranging from restrictions on gifts
to conflicts of interest. All employees are required annually to affirm in writing their acceptance of the code. This Code of
Business Conduct and Ethics is in accordance with NASDAQ Listing Rule 5610 and is published on the Company’s corporate website
– www.aceto.com. We intend to satisfy the disclosure requirement under Item 5.05(c) of Form 8-K regarding an amendment
to, or a waiver from, a provision of our Code of Business Conduct and Ethics by posting such information on our website, www.aceto.com.



Disclosure Committee



The
Company has formed a disclosure committee, comprised of senior management, including senior financial personnel, to formalize
processes to ensure accurate and timely disclosure in Aceto’s periodic reports filed with the United States Securities and
Exchange Commission and to implement certain disclosure controls and procedures. The disclosure committee operates under a formal
charter that governs its duties and conduct. The charter is published on the Company’s corporate website – www.aceto.com.



SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING
COMPLIANCE



Pursuant to Section 16
of the Exchange Act, the Company's directors, certain of the Company’s officers and beneficial owners of more than 10% of
the Company's Common Stock are required to file certain reports, within specified time periods, indicating their holdings of and
transactions in the Common Stock and derivative securities of Aceto. Based solely on a review of such reports provided to the Company
and written representations from such persons regarding the necessity to file such reports, the Company is not aware of any failures
to file reports or report transactions in a timely manner during the Company's fiscal year ended June 30, 2018 except for a late
Form 4 for one transaction for Frances Scally, Senior Vice President and Chief Accounting Officer that was filed approximately
one month late.



9







EXECUTIVE OFFICERS



Set forth below are the names of our executive
officers, their ages as of October 15, 2018, and their positions with Aceto.



|Name                             |  | Age |  | Position                                                     
|-------------------------------- |  | --- |  | -------------------------------------------------------------
|William
        C. Kennally, III |  | 62  |  | President
        and Chief Executive Officer                
|Rebecca
        Roof             |  | 63  |  | Chief
        Financial Officer                              
|Steven
        S. Rogers         |  | 57  |  | Senior
        Vice President and Chief Legal Officer        
|Charles
        J. Alaimo        |  | 52  |  | Senior
        Vice President, Human Resources               
|Frank
        DeBenedittis       |  | 64  |  | Senior
        Vice President, Corporate Business Development
|Frances
        P. Scally        |  | 51  |  | Senior
        Vice President and Chief Accounting Officer   



On September 24, 2018, Walter Kaczmarek,
III, Chief Operating Officer of the Company, notified the Company that he will resign from his role as Chief Operating Officer,
effective October 24, 2018, and is therefore excluded from the above table.



William C. Kennally, III. Mr. Kennally
is the Chief Executive Officer and President of Aceto and is a member of Aceto’s Board of Directors. Mr. Kennally joined
Aceto’s Board in September 2016 and in September 2017 was appointed President and Chief Executive Officer of the Company.
He retired from Pfizer in 2015 after 37 years of service, most recently as Regional President North America, Global Established
Pharma Division from 2014 to 2015 and Regional President North America, Global Established Products from 2010 to 2014. Both roles
involved leading three separate and distinct brand businesses and two generic businesses. From 2001 to 2009, Mr. Kennally was President
of Greenstone, LLC, a generic and authorized generic pharmaceutical supplier which became a wholly owned subsidiary of Pfizer,
Inc. after Pfizer’s acquisition of Pharmacia. Mr. Kennally started his professional career in Sales with the Upjohn Company,
which was later acquired by Pharmacia, and followed a Pharmaceutical Sales Career pathway that included front line management and
a corporate office position as Sales Incentive Compensation Manager. Mr. Kennally graduated from St. Anselm College with a B.S.
in Criminal Justice.



Rebecca Roof. Ms. Roof was appointed
Interim Chief Financial Officer of Aceto on April 18, 2018. Ms. Roof is employed by, and is Managing Director of AlixPartners LLP,
a global business advisory firm. Ms. Roof possesses more than 30 years of experience providing advisory and C-suite interim management
services for companies in a broad array of industries such as life sciences, healthcare, consumer, chemicals, energy and manufacturing.
She has previously led complex client engagements and served as Interim Chief Financial Officer of the Eastman Kodak Company, Anchor
Glass Corporation, Fleming Foods, and several other privately held entities. Ms. Roof also served as Interim Global Controller
of LyondellBasell Industries, the third-largest chemical company globally, where she helped lead the company through one of the
largest and most successful restructuring processes. Prior to that, Ms. Roof served as Chief Restructuring Advisor of TaroPharmaceutical
Industries, an international generic-drug manufacturer in strengthening its financial controls systems and as Interim Chief Financial
Officer of Atkins Nutritionals. In addition, Ms. Roof currently serves on the advisory boards of Texas Wall Street Women and Peach
Outreach and is a member of the United Way Women’s Initiative in Houston. Ms. Roof graduated from Trinity University with
a B.S. and B.A. in Business Administration and Geology.



Steven S. Rogers. Mr. Rogers has
been Senior Vice President, Chief Legal Officer and Secretary of the Company since April 2016, Senior Vice President, General Counsel
and Secretary of the Company since October 2011 and Vice President, General Counsel and Secretary since January 2011. Prior to
joining the Company, Mr. Rogers was the General Counsel of Rising, certain assets of which the Company acquired in December 2010.
Mr. Rogers oversees all legal and regulatory matters and provides legal counsel to the Company’s senior management and the
Board. From 1986 to 1994, Mr. Rogers was a corporate litigator at Kelley Drye & Warren LLP. From 1994 to 1997, he was Associate
General Counsel/First Vice-President of PaineWebber, Inc. From 1997 to 2009, he served as General Counsel of LibertyView Capital
Management, a SEC-registered investment adviser, owned by Credit Agricole and then Neuberger Berman, LLC, where he was responsible
for all legal, compliance and regulatory matters and oversaw the research and risk departments. Mr. Rogers earned his J.D. from
the Fordham University School of Law in 1986 and a B.A. in History from the State University of New York at Binghamton in 1983.
He is a member of the New York and Connecticut State Bars, as well as various federal courts including the United States Supreme
Court.



10







Charles J. Alaimo. Mr. Alaimo has
been Senior Vice President, Human Resources of the Company since July 2012 and Vice President, Human Resources, since January 2011.
Mr. Alaimo oversees the global human resources functions. Prior to joining the Company, from 2008 to 2011, Mr. Alaimo was Director,
Global Human Resources for Coby Electronics where he oversaw all human resources activities for this private consumer electronics
company. From 2004 to 2007, he was Director, Human Resources and General Affairs for TDK Electronics Corporation. Mr. Alaimo also
served as Regional Manager, Human Resources for Group One Trading, LP, a private, derivatives trading firm, from 2000 to 2004.
Mr. Alaimo earned his B.B.A. in Human Resources Management from Baruch College in 1989 and a M.S. in Industrial and Labor Relations
from Baruch College in 2005.



Frank DeBenedittis. Mr. DeBenedittis
has served as Senior Vice President, Corporate Business Development since August 2011 and International Senior Vice President,
Active Pharmaceutical Ingredients since February 2011. Prior to that, Mr. DeBenedittis was Executive Vice President since January
2009 and Senior Vice President of the Company since 2001. Mr. DeBenedittis joined the Company in 1979 as a marketing assistant
and held various positions within the Company including Assistant Product Manager, Product Manager, Assistant Vice President and
Vice President. In addition, Mr. DeBenedittis currently serves on the board of directors of Rising Pharmaceuticals, Inc. (“Rising”)
a wholly owned subsidiary of the Company. Mr. DeBenedittis holds a B.A. in Chemistry from Stony Brook University.



Frances
P. Scally. Ms. Scally has been Senior Vice President and Chief Accounting Officer since October 2017. Ms. Scally joined the
Company in 2007 as a Director, Financial Reporting and Compliance, and became the Company’s Vice President, Financial Reporting,
Compliance and Risk in October 2014. From 1998-2007, Ms. Scally was the Director of Financial Reporting and Compliance at Veeco
Instruments Inc. Previously, Ms. Scally was a Senior Manager with Ernst & Young LLP, where she was employed from 1989-1998.
Ms. Scally received a bachelor’s degree in accounting from LIU Post and is a Certified Public Accountant. She is a member
of New York State Society of CPAs, American Institute of Certified Public Accountants and the Institute of Internal Auditors. Ms.
Scally is a Trustee and a member of the Finance Committee for St. Edward the Confessor Church and School.



11







Item 11. Executive Compensation



COMPENSATION DISCUSSION AND ANALYSIS



Executive Summary



The mission of our Compensation Committee
is to ensure that the programs for executive and staff compensation best help the Company achieve its strategic goals and include
best practices of our industry.



The objectives of our compensation program
are to:





| | · | provide compensation and benefit plans that are equitable to our executives and other employees
as well as our shareholders;
| | - | ----------------------------------------------------------------------------------------------------------------------------

| | · | enable us to attract, motivate and retain highly qualified, experienced talent; and
| | - | -----------------------------------------------------------------------------------

| | · | align our rewards with long term corporate goals as well as shareholder expectations and value.
| | - | -----------------------------------------------------------------------------------------------



We strive to reward our named executive
officers fairly and competitively through a properly balanced mix of base salary, short-term and long-term incentives, benefits,
career growth and development opportunities. We believe this mix drives company performance and assists with employee retention.
We do this by weighting the compensation of our named executive officers toward long-term incentives over salary and annual cash
incentives. We regularly review our executives’ compensation against our own selected peer group, and we review the composition
of our peer group annually. Historically, our compensation program has provided a strong balance of retention and ownership with
a direct linkage to the Company’s strategic objectives, operating and shareholder performance.



When we refer to our “named executive
officers” in this Amendment, we are referring to our chief executive officers throughout our last fiscal year, our chief
financial officers throughout our last fiscal year and our three most highly compensated executive officers other than our chief
executive officer and chief financial officer who were serving as executive officers as of June 30, 2018. Our named executive officers
for our fiscal year ended June 30, 2018 were the following individuals:



William C. Kennally,
III, President and Chief Executive Officer

Salvatore Guccione,
Former President and Chief Executive Officer

Rebecca Roof, Chief
Financial Officer

Edward Borkowski, Former
Chief Financial Officer

Douglas Roth, Former
Chief Financial Officer

Walter Kaczmarek, III,
Chief Operating Officer

Steven S. Rogers, Senior
Vice President and Chief Legal Counsel

Albert L. Eilender,
Chairman Emeritus



Our Compensation Philosophy and Objectives



The philosophy of the Compensation Committee
is to ensure that the strategic vision of our executive team is supported by modern compensation practices that reward achievement
and creation of shareholder value.



Consistent with those purposes, our compensation
program employs the following principles:



| | • | compensation among our executives and staff should be equitable regardless of gender, race, religion
or sexual orientation;
| | - | ---------------------------------------------------------------------------------------------------------------------------



| | • | the compensation program should pay for performance, that is, reward the achievement of our strategic
initiatives and short-term and long-term operating and financial goals, and provide disincentives for underperformance;
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • | compensation should reflect differences in position and responsibility;
| | - | -----------------------------------------------------------------------



12







| | • | compensation should be comprised of a mix of cash and equity-based compensation that aligns the
short-term and long-term interests of our executives with those of the Company, the corporation’s strategy and our shareholders;
and
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • | the compensation program should be understandable and transparent.
| | - | ------------------------------------------------------------------



In structuring a compensation program that
implements these principles, we have developed the following strategies for our executive compensation program:



| | • | overall compensation levels should be competitive with our peers and should be set at levels that
allow us to attract and retain talented leaders and motivate them to achieve superior results;
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • | a majority of total compensation should be contingent on, and variable with, achievement of objective
corporate performance goals;
| | - | ----------------------------------------------------------------------------------------------------------------------------------



| | • | total compensation should be higher for individuals with greater responsibility and greater ability
to influence achievement of our operating and financial goals and strategic initiatives;
| | - | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • | the number of different elements in our compensation program should be limited, and those elements
should be stable year-over-year, and effectively communicated to and understood by executives and shareholders; and
| | - | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • | compensation should be set at levels that promote a sense of equity among all employees while giving
due regard to any premiums that may be necessary in our industry in order to attract top talent at the executive level.
| | - | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



This past fiscal year
was focused on stabilizing our generic drug business in a very competitive environment, on effectively managing the Company’s
other business units, and on exploring strategic alternatives for our company as a whole. The compensation strategy therefore
was adjusted toward policies for senior staff retention, and for stabilization of corporate operations through greater emphasis
in fiscal 2019 on cash compensation and performance-based cash bonuses, consistent with our other compensation strategies.



Consideration of Last Year’s
“Say on Pay” Advisory Vote



At last year’s annual meeting of
shareholders, we held an advisory shareholder vote on executive compensation.  More than 95% of the shares that voted approved
our executive compensation described in last year’s proxy statement. The Compensation Committee viewed the results of
this vote as a strong indication that the Company’s shareholders support the compensation policies and practices of the Company. 
Accordingly, the results of this vote did not affect the Company's executive compensation decisions and policies for our named
executive officers during the fiscal year ended June 30, 2018.



CEO Pay Ratio



Pursuant to Section 953(b) of the Dodd-Frank
Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are required to disclose the ratio of our
principal executive officer’s annual total compensation to the annual total compensation of our median employee.



For the fiscal year
ended June 30, 2018:



| | · | The median of the annual total compensation of all of our employees, other than our CEO, was $78,185;
and
| | - | ---------------------------------------------------------------------------------------------------------

| | · | The annual total compensation of our CEO, was $1,913,807.
| | - | ---------------------------------------------------------



Based on this information,
for fiscal 2018, the ratio of the annual total compensation of Mr. Kennally, our CEO, to the median of the annual total compensation
of all employees other than our CEO, was 24 to 1.



To identify the median of the
annual total compensation of all of our employees, as well as to determine the annual total compensation of our “median employee”
and our CEO, we took the following steps:



| | 1. | We determined that as of June 1, 2018, our employee
population consisted of approximately 315 employees.
| | -- | --------------------------------------------------------------------------------------------------------



| | 2. | To identify the “median employee” from
our employee population, we compared the annual base salary and the target performance award for fiscal 2018 for all of our employees
other than the CEO.
| | -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 3. | Once we identified our median employee, we recalculated
the median employee’s compensation for fiscal 2018 in accordance with the requirements of Item 402(c)(2)(x) of Regulation
S-K, resulting in annual total compensation of $78,185.
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 4. | With respect to the annual total compensation of our
CEO, since Mr. Kennally began serving as CEO on October 2, 2017, we have annualized his salary for fiscal 2018, resulting in annual
total compensation for Mr. Kennally of $1,913,807 (when added to the other components of his compensation disclosed in the Summary
Compensation Table).  Please note that as a result of annualizing Mr. Kennally’s salary, the total annual compensation
we used for this pay ratio disclosure is different than Mr. Kennally’s total annual compensation as included in the Summary
Compensation Table, in accordance with SEC rules.
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



13







The pay ratio reported above is a reasonable
estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. The
SEC rules for identifying the median-compensated employee and calculating the pay ratio based on that employee’s annual total
compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates
and assumptions that reflect their employee populations and compensation practices. Therefore, the pay ratio reported by other
companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation
practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.



Elements of Our Executive Compensation



Our executive compensation program has
historically been comprised of base salary, performance-based annual cash incentives, long-term equity incentive awards and fringe
benefits. These elements of compensation have been supplemented by benefit plans to which the Company contributes, including our
401(k) plan and our supplemental executive retirement plan, as well as life insurance premiums paid by the Company for employee
life insurance policies. We use our experience and judgment to determine what is the appropriate mix of compensation elements
for each executive. In allocating compensation among the various elements, the Compensation Committee considers many factors including
market data, Company performance, individual performance, the impact of the executive’s position on the Company, individual
past performance, experience in the position, any anticipated increase in the individual’s responsibilities, internal pay
equity for comparable positions, and succession planning and retention strategies.



With the adoption of the Aceto Corporation
2010 Equity Participation Plan (the “2010 Plan”) in December 2010 and the Aceto Corporation 2015 Equity Participation
Plan (the “2015” Plan) in December 2015, our long-term incentive compensation component was increased for our named
executive officers, making a significant and in some cases majority portion of their annual total direct compensation dependent
on long-term stock appreciation and long-term company financial and operating performance. Due to the current competitive business
environment and the need to consider strategic alternatives while retaining key executives, we anticipate that our compensation
policies in the near future will be more heavily weighted toward cash-based compensation and performance bonuses.



Our executive
compensation program and policies are driven by our business environment and designed to enable us to achieve our mission and
adhere to our values. The Compensation Committee and senior management continually evaluate the relationship between risk and
reward as it relates to our executive compensation program and have adopted policies and practices that mitigate undue risk while
preserving the incentive/variable nature of the compensation.



In fiscal 2018, senior management
performed a formal assessment of the Company’s global compensation programs, policies and practices based on generally
accepted compensation practices. Each compensation program was assigned a risk rating of low, moderate, or high. In assigning
the risk rating, a number of factors were considered, including, among other things, whether the plan features include capped
payouts or deferrals and/or clawbacks, whether the plan design or administration leads to outsized risk taking, and whether
payments are based on pre-established performance goals including risk-adjusted metrics.



The results of the assessment were reviewed
by FW Cook and discussed with the Compensation Committee during fiscal 2018. The assessment reaffirmed our belief that our compensation
programs and policies are structured and operated in a manner that does not create risks that are reasonably likely to have a material
adverse effect on our business. In addition to ongoing monitoring of our programs and policies, we are committed to performing
formal assessments on an annual basis.



The
pie charts below show that most of our named executive officers’ target compensation for fiscal 2018 was variable (73% for
CEO and an average of 63% for our other named executive officers). Variable pay includes the target value of short-term cash incentives
and restricted stock.



14









| | 
| | 



Our peer group was reviewed with FW
Cook in fiscal 2017 and at that time, it was decided to change our peer group to a new peer group consisting of 15 companies
selected by us to reflect our current business strategy of focusing more on the end market pharmaceutical space. These
companies included in the peer group reflect Aceto’s business strategy, placing greater emphasis on companies whose
primary business is tied to health care. The selection criteria to evaluate the peer group companies included comparable
business content/model, company size, business characteristics and executive talent. During the fiscal year, we reviewed our
peer group with FW Cook and determined that Albany Molecular Research and Sagent Pharmaceuticals, which were in the peer
group in 2017, were acquired and were replaced by AMAG Pharmaceuticals Inc. and Luminex Corp. During the 2018 fiscal year,
the peer group companies included: Akorn Inc., AMAG Pharmaceuticals Inc., American Vanguard Corporation, Amphastar
Pharmaceuticals, ANI Pharmaceuticals, Cambrex Corporation, Depomed, Impax Laboratories, Inc., Innophos Holdings, Inc.,
Lannett Company, Inc., Lawson Products, Inc., Luminex Corp., Prestige Brand Holdings, Inc., Quaker Chemical Corporation and
Usana Health Sciences, Inc. AMAG Pharmaceuticals Inc. was added because it increased the weighting of pharmaceutical
companies in the peer group and has similar revenue and market cap to Aceto. Luminex Corp. was added to the peer group during
the 2018 fiscal year due to its strong focus on research and development. During the 2018 fiscal year, our compensation
consultant conducted a benchmarking review consisting of a competitive review of executive compensation levels for
certain executive officers, including our named executive officers. The analysis focused on target compensation in order to
provide market competitive comparisons for setting executive compensation opportunities. The Compensation Committee’s
benchmarking criteria for these purposes included comparisons of executive base salary compensation, performance awards, long
term incentive compensation, total cash compensation (base salary plus annual performance awards), and total direct
compensation (total cash compensation plus long-term incentive compensation) of our peer group. Based upon the results of the
study, it was determined that Aceto’s executive officers cash compensation generally approximates median levels and
most executive officers target bonus was at or above the median. For long-term incentives, the Company’s executive
officers were positioned slightly below the market median. Aceto’s target total direct compensation was positioned
approximately 11% above the market overall median. The overall positioning at median is aligned with Aceto’s strategy
for fiscal 2018 of aggregate positioning at the market median and increased emphasis on long-term incentives as compared to
cash compensation.



Base Salary



We provide our named executive officers
with base salary to provide them with a fixed base amount of compensation for services rendered during a fiscal year. We believe
this is consistent with competitive practices and will help assure our retention of qualified leadership in those positions. We
intend to maintain base salaries at competitive levels in the marketplace for comparable executive ability and experience, taking
into consideration changes from time to time in the consumer price index and whether competitive adjustments are necessary to promote
retention. Consideration also is given in each case to the historical results achieved by each executive and the Company during
each executive’s tenure, to whether each executive is enhancing the team-oriented nature of the executive group, the potential
of each executive to achieve future success, and the scope of responsibilities and experience of each executive. In addition, evaluations
are made regarding the competencies of each named executive officer that are considered essential to our success.





The Compensation Committee evaluated the
historical performance of our executive officers and considered the compensation levels and programs within the peer group before
it made its fiscal 2018 compensation recommendations to the full board. As previously discussed, FW Cook completed an assessment
during the 2018 fiscal year that reviewed the compensation program for certain executive officers, including our named executive
officers, regarding base pay, performance awards and long-term incentive compensation. The report indicated that the pay mix for
Aceto’s executive officers is weighted more toward long-term incentive compensation than the companies included in the peer
group.



15







Annual Performance Awards



We grant annual performance awards to encourage
achievement of goals established for our short-term and long-term financial and operating results, and to reward our named executive
officers for consistent performance in assisting us in achieving those goals. Pre-determined annual performance measures were utilized
in connection with our performance awards for the fiscal year ended June 30, 2018.



For our fiscal year ended June 30, 2018,
the annual performance award criteria for 85% of the awards payable under our Executive Award Plan established by our Compensation
Committee, and approved by the Board, were based upon results obtained with respect to the following four financial factors: (1)
company sales; (2) company gross profit; (3) company net income; and (4) company earnings per share. For the named executive officers,
the financial factors were weighted at 15% for company sales, 10% for company gross profit, 30% for company net income, 30% for
company earnings per share and the individual performance goals (which are qualitative in nature) were weighted at 15%. The specific
performance-related financial factors at the minimum, target and maximum levels for the fiscal year ended June 30, 2018 were:



|Performance Metric         |  | Minimum |             |  | Target |   |             | Maximum |  |   | Actual Results | 
|-------------------------- |  | ------- | ----------- |  | ------ | - | ----------- | ------- |  | - | -------------- | 
|Company Sales              |  | $       | 590,420,250 |  |        | $ | 787,227,000 |         |  | $ | 1,180,840,500  | 
|Company Gross Profit       |  | $       | 135,332,250 |  |        | $ | 180,443,000 |         |  | $ | 270,664,500    | 
|Company Net Income         |  | $       | 36,075,000  |  |        | $ | 48,100,000  |         |  | $ | 72,150,000     | 
|Company Earnings Per Share |  | $       | 1.03        |  |        | $ | 1.37        |         |  | $ | 2.06           | 



*Adjusted for certain charges including
asset impairment charges, valuation allowances, and environmental remediation charges.



The annual award percentages at the minimum,
target and maximum levels for the fiscal year ended June 30, 2018 for each of the named executive officers were as follows:



|Executive Officer     |  | Minimum            |  | Target              |  | Maximum            
|--------------------- |  | ------------------ |  | ------------------- |  | -------------------
|William Kennally, III |  | 50% of base salary |  | 100% of base salary |  | 200% of base salary
|Walter Kaczmarek, III |  | 30% of base salary |  | 60% of base salary  |  | 120% of base salary
|Albert L. Eilender    |  | 30% of base salary |  | 60% of base salary  |  | 120% of base salary
|Steven S. Rogers      |  | 25% of base salary |  | 50% of base salary  |  | 100% of base salary



The following describes the performance-based
bonus criteria for each named executive officer:



William Kennally
III, President and Chief Executive Officer. Mr. Kennally’s 2018 annual performance award was $130,652 and reflected,
on an individual performance basis, preparation of a three-year budget plan, followed by preparation of a budget plan for four
and five years after fiscal 2018, which was added to prepare the company for strategic alternatives options.



16







Walter Kaczmarek
III, Chief Operating Officer. Mr. Kaczmarek’s 2018 annual performance award was $78,672 and reflected, on an individual
performance basis, meeting with the top 2-3 suppliers/customers of each of the non-Rising Business Units.



Steven S.
Rogers, Senior Vice President. Mr. Rogers’s 2018 annual performance award was $49,688 and reflected, on an
individual performance basis, implementing training for certain policy issues including antitrust compliance. In addition,
Mr. Rogers received $95,400 pursuant to a retention agreement Mr. Rogers entered into with the Company. See “Retention
Arrangements.”



Albert L. Eilender,
Chairman Emeritus Mr. Eilender’s 2018 annual performance award was $78,592 and reflected, on an individual performance
basis, developing a succession plan for the Chairman of the Board and presenting the recommendation to the Board.



The Compensation Committee recommended
and the Board approved continued emphasis on the use of objective performance criteria to determine annual performance awards for
the fiscal year ended June 30, 2018. The precise criteria that we will use to determine the annual performance award for our executive
officers will vary depending on each officer’s specific responsibilities. In all cases, annual performance awards paid to
any one individual cannot exceed two times the individual’s base salary.



Long-Term Incentive Compensation



Based upon the reviews by our compensation
consultant in fiscal 2018 as well as in prior years, our Compensation Committee recommended that our compensation mix include a
greater proportion of long-term incentive compensation. During fiscal 2018, we continued to place increasing emphasis on compensation
tied to the Company’s strategic objectives, long-term financial and operating performance. These incentives were intended
to further align management’s interest with the interests of our shareholders.



For fiscal 2018, our Compensation Committee
recommended and the Board approved, a three year long term incentive compensation program pursuant to the 2015 Plan consisting
of restricted stock and performance-vested restricted stock units for our executive officers. The restricted stock awards vest
over three years. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following the grant
upon the attainment of pre-tax income and total shareholder return performance goals relative to the Russell 2000 Index. The number
of shares subject to the 2018 long term incentive awards is set forth in the table entitled “2018 Grants of Plan-Based Awards.”



Recoupment of Awards



Each performance award paid shall for a
period of two years (or such longer period as the Compensation Committee may determine in its discretion) be subject to forfeiture,
cancelation and/or repayment to the Company if: (i) the payment of such award (or portion thereof) was predicated upon the achievement
of certain financial results or other performance criteria; (ii) in the Compensation Committee’s view, the participant either
benefited from a calculation that later proves to be materially inaccurate, or engaged in one or more material acts of fraud or
misconduct that caused or partially caused the need for a financial restatement by the Company; and (iii) in the Compensation Committee’s
view, a lesser payment (or no payment) of such award would have occurred based on a correct calculation or upon restated financial
results or other performance criteria.



Retention Arrangements



In May 2018, we entered into retention
bonus agreements with certain key employees, none of whom were named in the Summary Compensation Table in last year’s proxy
statement and only one of whom (Steven Rogers) is referred to as a named executive officer in this Amendment. These arrangements
were designed to retain key employees during a critical period of time as we began examining strategic alternatives for our company
in an extremely difficult business environment. To assure the retention of our key employees during this and future periods, we
assured them bonuses if they remained employed by us through certain dates: 10% of each participant’s bonus was payable on
May 31, 2018, 15% of each participant’s bonus was payable on August 31, 2018 and the balance of each participant’s
bonus is payable on September 13, 2019, subject to acceleration in certain instances and subject to proration in other instances
relating to termination by us without cause or by the participants for good reason. A total of 31 key employees were covered by
these arrangements, with aggregate payments of $905,545 and $1,349,580 made on May 31, 2018 and August 31, 2018, respectively.



17







Other Compensation



Our U.S. executive officers may also participate
in our 401(k) plan on the same terms as the rest of our eligible employees. We currently make a non-elective contribution on behalf
of each of our participating employees equal to 3% of the participant’s eligible compensation, including base salary and
bonus, up to a maximum of $270,000 of eligible compensation. We also have historically made discretionary contributions for each
of our participating employees on an annual basis up to approximately 8% of the participant’s eligible compensation. Our
participating employees are fully vested in both their salary deferrals and non-elective contributions, but Company discretionary
contributions vest at the rate of 20% per year with 100% vesting after five years of participation.



We also maintain a supplemental executive
retirement plan, commonly called a “SERP”. This plan is a non-qualified deferred compensation plan intended to provide
executive officers with supplemental retirement benefits. Annual Company contributions to the SERP are fixed by the Board and vest
at the rate of 20% per year of service over five consecutive years. In addition to Company contributions, participants can elect
to defer some or all of their bonus compensation into their SERP account for the following year.



Perquisites



We allow certain of our executive officers
to use a Company automobile as a perquisite to enhance our compensation package and make it more attractive relative to our competition.
The financial value of the personal use of a Company automobile for each of the named executive officers for our fiscal year ended
June 30, 2018 is set forth in footnote twelve to the All Other Compensation column of the Summary Compensation Table contained
herein.



Stock Ownership Requirements



In order to further align management’s
interest with the interests of our shareholders, our Compensation Committee established, and the Board approved, stock ownership
requirements for our Chief Executive Officer, our Chief Financial Officer and our three other most highly compensated executive
officers. These stock ownership requirements provide that our Chief Executive Officer must own shares of our common stock valued
at three times his base salary and our Chief Financial Officer and our other three most highly compensated executive officers must
own shares of our common stock valued at one and a quarter times their base salaries. Mr. Kennally has until October of 2022 to
meet this requirement. Due to the decline in the stock price (the closing stock price of our Common Stock at June 30, 2018 was
$3.35), the named executive officers no longer meet this requirement. The stock ownership program also includes as a guideline,
but not a requirement, that all our other executive officers own shares of our common stock valued at one half times base salary
by such date. Shares of our restricted stock that are granted but not yet vested count toward these stock ownership guidelines.



The stock ownership program also includes
as a guideline, but not a requirement, that all non-employee directors achieve a level of ownership of our common stock, including
restricted stock granted but not yet vested, valued at five times the annual cash retainer by January 2020.



Tax and Accounting Implications of
Executive Compensation



Section 162(m) of the Internal Revenue
Code of 1986, as amended, generally disallows a tax deduction for compensation in excess of $1 million paid in a taxable year by
a publicly held corporation to its chief executive officer and certain other “covered employees”. For 2017 and prior
taxable years, an exception to this deduction limit applied to “performance-based compensation”, such as stock options
and other equity awards that satisfied certain criteria. Under the federal tax reform legislation signed into law on December 22,
2017, the performance-based pay exception to Section 162(m) was eliminated, but a transition rule may allow the exception to continue
to apply to certain performance-based compensation in effect on November 2, 2017. While the Compensation Committee considers the
impact of Section 162(m) on our compensation program, it reserves the right to pay nondeductible compensation if it determines
that it is appropriate to do so. It is our policy to review all compensation plans and policies against tax, accounting, and SEC
regulations, including Section 162(m), Internal Revenue Code Section 409A, and generally accepted accounting principles.



18







COMPENSATION COMMITTEE REPORT



The Compensation Committee has reviewed
and discussed with management the Compensation Discussion and Analysis included in this Amendment. Based on that review and discussion,
the Compensation Committee recommended to the Board that the Compensation Discussion and Analysis be included in this Amendment.



Natasha Giordano (Chairperson)

Alan G. Levin

Daniel B. Yarosh, Phd.



19







EXECUTIVE COMPENSATION



SUMMARY COMPENSATION TABLE



The following table sets forth certain
information regarding the compensation of our named executive officers for the fiscal year ended June 30, 2018 and, where applicable,
for the fiscal years ended June 30, 2017 and June 30, 2016. Except as set forth below, no other compensation was paid to these
individuals during the years presented.



|Name and Principal Position              |  | Year |  | Salary($) |         |  | Bonus ($)(1) |   |         | Stock Awards ($)(2) |  |   | Option Awards ($)(3) |  |  | Non-Equity Incentive Plan Compensation ($)(4) |         |  | All Other Compen- sation ($)(12) |   |         | Total ($) | 
|---------------------------------------- |  | ---- |  | --------- | ------- |  | ------------ | - | ------- | ------------------- |  | - | -------------------- |  |  | --------------------------------------------- | ------- |  | -------------------------------- | - | ------- | --------- | 
|                                         |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|William C. Kennally, III                 |  | 2018 |  | $         | 436,781 |  |              | $ | -       |                     |  | $ | 1,070,650            |  |  | $                                             | -       |  |                                  | $ | 130,652 |           | 
|President and Chief Executive            |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|Officer (5)                              |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|                                         |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|Salvatore Guccione                       |  | 2018 |  |           | 939,440 |  |              |   | -       |                     |  |   | 832,654              |  |  |                                               | -       |  |                                  |   | -       |           | 
|Former President and Chief               |  | 2017 |  |           | 619,914 |  |              |   | -       |                     |  |   | 1,134,423            |  |  |                                               | 149,600 |  |                                  |   | 282,749 |           | 
|Executive Officer (6)                    |  | 2016 |  |           | 605,205 |  |              |   | -       |                     |  |   | 1,441,823            |  |  |                                               | -       |  |                                  |   | 394,908 | (7)       | 
|                                         |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|Rebecca Roof (8) Chief Financial Officer |  | 2018 |  |           | 625,000 |  |              |   | -       |                     |  |   | -                    |  |  |                                               | -       |  |                                  |   | -       |           | 
|                                         |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|Edward Borkowski (9)                     |  | 2018 |  |           | 78,208  |  |              |   | 100,000 |                     |  |   | 439,800              |  |  |                                               | -       |  |                                  |   | -       |           | 
|Former Chief Financial Officer           |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|                                         |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|Douglas Roth (10)                        |  | 2018 |  |           | 349,723 |  |              |   | -       |                     |  |   | 478,891              |  |  |                                               | -       |  |                                  |   | -       |           | 
|Former Chief Financial Officer           |  | 2017 |  |           | 377,060 |  |              |   | -       |                     |  |   | 617,042              |  |  |                                               | -       |  |                                  |   | 114,654 |           | 
|                                         |  | 2016 |  |           | 368,100 |  |              |   | -       |                     |  |   | 782,785              |  |  |                                               | -       |  |                                  |   | 217,009 | (7)       | 
|                                         |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|Walter Kaczmarek, III (11)               |  | 2018 |  |           | 488,976 |  |              |   | -       |                     |  |   | 425,541              |  |  |                                               | -       |  |                                  |   | 78,672  |           | 
|Chief Operating Officer                  |  | 2017 |  |           | 429,327 |  |              |   | 150,000 |                     |  |   | 1,610,600            |  |  |                                               | -       |  |                                  |   | 169,037 |           | 
|                                         |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|Albert L. Eilender                       |  | 2018 |  |           | 488,750 |  |              |   | -       |                     |  |   | 801,892              |  |  |                                               | -       |  |                                  |   | 78,592  |           | 
|Chairman Emeritus                        |  | 2017 |  |           | 455,649 |  |              |   | -       |                     |  |   | 1,081,533            |  |  |                                               | -       |  |                                  |   | 173,930 |           | 
|                                         |  | 2016 |  |           | 425,000 |  |              |   | -       |                     |  |   | 1,204,940            |  |  |                                               | -       |  |                                  |   | 255,922 |           | 
|                                         |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 
|Steven S. Rogers (11)                    |  | 2018 |  |           | 370,592 |  |              |   | 95,400  |                     |  |   | 335,335              |  |  |                                               | -       |  |                                  |   | 49,688  |           | 
|Chief Legal Officer                      |  |      |  |           |         |  |              |   |         |                     |  |   |                      |  |  |                                               |         |  |                                  |   |         |           | 



(1) Bonuses paid during
2018, 2017 and 2016 pursuant to the Company’s bonus plan are reflected under the column entitled “Non-Equity
Incentive Plan Compensation.”  The Company did not pay discretionary bonuses during 2018, 2017 and 2016 with the
exception of a retention bonus paid to Mr. Rogers in 2018,  a sign-on bonus paid to Mr. Kaczmarek in 2017 and a
sign-on bonus paid to Mr. Borkowski which he returned to the Company subsequent to his termination; all other bonuses were
performance-based.



(2)Amounts shown in this column
reflect the aggregate grant date fair value of restricted stock awards and restricted stock units granted during the year computed
in accordance with generally accepted accounting principles.



(3)Amounts shown in this column
reflect the aggregate grant date fair value of stock option awards granted during fiscal 2017 computed in accordance with generally
accepted accounting principles. There were no stock options granted to our named executive officers during fiscal 2018 and 2016.



(4)Reflects cash bonuses under
the Company’s bonus plan. Bonuses listed for a particular year represent bonuses earned with respect to such year even though
the bonuses were paid during the first quarter of the subsequent year.



(5) Mr. Kennally served as a non-employee
director of the Company prior to fiscal 2018 and for portions of fiscal 2018, but was not employed by the Company prior to fiscal
2018. Mr. Kennally’s “Total Other Compensation” includes $20,874 that he received during fiscal 2018 as compensation
for serving as a non-employee director before being named our chief executive officer.



20







(6)In connection with Mr. Guccione’s
resignation on September 27, 2017, the Company agreed to pay to Mr. Guccione severance equal to twenty-four (24) months of base
salary ($1,271,260 in the aggregate),payable in substantially equal installments for a period
equal to twenty-four (24) months following Mr. Guccione’s separation date, which was September 27, 2017, and a lump sum cash
payment equal to the amount of Mr. Guccione’s performance awards for the prior two years ($677,657 in the aggregate). The
Company also agreed to provide for the acceleration, in the manner set forth in the Employment Agreement, of the vesting of all
outstanding unvested stock options, restricted stock units and restricted stock awards the Company previously granted to Mr. Guccione.



(7) The bonus amount for Mr. Guccione
includes $39,491 of restricted stock, which was received by Mr. Guccione in lieu of a portion of his bonus for fiscal year 2016.
The bonus amount for Mr. Roth includes $18,021 of restricted stock, which was received by Mr. Roth in lieu of a portion of his
bonus for fiscal year 2016.



(8) On April 18, 2018, the
Company named Rebecca Roof to serve as its interim chief financial officer at a cost of $250,000 per month, payable to Ms.
Roof’s employer AP Services LLC, an affiliate of AlixPartners LLP. Ms. Roof is an employee of AlixPartners and does not
receive compensation directly from the Company. Under our agreement with AP Services LLC, we also reimburse AlixPartners for
expenses relating to Ms. Roof during the year ended June 30, 2018. The amount shown in the table reflects amounts paid by the
Company to AP Services LLC in connection with Ms. Roof’s services to the Company. Since Ms. Roof is not an employee of
the Company, she does not participate in any of the compensation programs or employee benefits arrangements discussed
herein.



(9) The salary for Mr.
Borkowski represents compensation for approximately two months, as he was only employed by the Company for that
time.



(10)Mr. Roth retired effective
March 31, 2018. In addition, in connection with Mr. Roth’s retirement, 44,902 shares of restricted stock with a fair value
of $431,000 became vested.



(11) Reflects the periods during
which Mr. Kaczmarek and Mr. Rogers were named executive officers.



(12) All Other Compensation
consists, in general, of the personal use of a Company owned automobile, contributions to retirement plans, reimbursement of
relocation expenses and compensation recognized from the issuance of premium shares of restricted stock as described in
footnote 13 as follows:



|Name             |  | Year |  |  | Company
 Automobile ($) |        |  | Company 
Contributions to 
Retirement 
Plans ($) |   |        | Issuance of 
premium 
shares of 
restricted
 stock  ($) (13) |  |   | Relocation 
Expenses ($) (14) |  |  | Other |         |  | Total Other 
Compensation ($) |  
|---------------- |  | ---- |  |  | ----------------------- | ------ |  | ------------------------------------------------ | - | ------ | ------------------------------------------------------------ |  | - | ----------------------------- |  |  | ----- | ------- |  | ----------------------------- | -
|                 |  |      |  |  |                         |        |  |                                                  |   |        |                                                              |  |   |                               |  |  |       |         |  |                               |  
|W. Kennally, III |  | 2018 |  |  | $                       | 2,024  |  |                                                  | $ | 44,231 |                                                              |  | $ | -                             |  |  | $     | -       |  |                               | $
|                 |  |      |  |  |                         |        |  |                                                  |   |        |                                                              |  |   |                               |  |  |       |         |  |                               |  
|S. Guccione      |  | 2018 |  |  |                         | 13,363 |  |                                                  |   | 8,100  |                                                              |  |   | -                             |  |  |       | -       |  |                               |  
|                 |  | 2017 |  |  |                         | 18,321 |  |                                                  |   | 66,534 |                                                              |  |   | 5,418                         |  |  |       | -       |  |                               |  
|                 |  | 2016 |  |  |                         | 18,133 |  |                                                  |   | 71,407 |                                                              |  |   | 12,415                        |  |  |       | -       |  |                               |  
|                 |  |      |  |  |                         |        |  |                                                  |   |        |                                                              |  |   |                               |  |  |       |         |  |                               |  
|E. Borkowski     |  | 2018 |  |  |                         | -      |  |                                                  |   | 1,982  |                                                              |  |   | -                             |  |  |       | -       |  |                               |  
|                 |  |      |  |  |                         |        |  |                                                  |   |        |                                                              |  |   |                               |  |  |       |         |  |                               |  
|R. Roof          |  | 2018 |  |  |                         | -      |  |                                                  |   | -      |                                                              |  |   | -                             |  |  |       | -       |  |                               |  
|                 |  |      |  |  |                         |        |  |                                                  |   |        |                                                              |  |   |                               |  |  |       |         |  |                               |  
|D. Roth          |  | 2018 |  |  |                         | 9,539  |  |                                                  |   | 29,948 |                                                              |  |   | -                             |  |  |       | -       |  |                               |  
|                 |  | 2017 |  |  |                         | 9,495  |  |                                                  |   | 45,987 |                                                              |  |   | 2,142                         |  |  |       | -       |  |                               |  
|                 |  | 2016 |  |  |                         | 9,984  |  |                                                  |   | 50,656 |                                                              |  |   | 6,148                         |  |  |       | -       |  |                               |  
|                 |  |      |  |  |                         |        |  |                                                  |   |        |                                                              |  |   |                               |  |  |       |         |  |                               |  
|W. Kaczmarek     |  | 2018 |  |  |                         | 13,071 |  |                                                  |   | 51,685 |                                                              |  |   | -                             |  |  |       | 37,101  |  |                               |  
|                 |  | 2017 |  |  |                         | 1,299  |  |                                                  |   | 61,217 |                                                              |  |   | -                             |  |  |       | 245,161 |  |                               |  
|                 |  |      |  |  |                         |        |  |                                                  |   |        |                                                              |  |   |                               |  |  |       |         |  |                               |  
|A. Eilender      |  | 2018 |  |  |                         | 5,318  |  |                                                  |   | 49,815 |                                                              |  |   | -                             |  |  |       | -       |  |                               |  
|                 |  | 2017 |  |  |                         | 6,577  |  |                                                  |   | 52,880 |                                                              |  |   | -                             |  |  |       | -       |  |                               |  
|                 |  | 2016 |  |  |                         | 8,092  |  |                                                  |   | 55,447 |                                                              |  |   | -                             |  |  |       | -       |  |                               |  
|                 |  |      |  |  |                         |        |  |                                                  |   |        |                                                              |  |   |                               |  |  |       |         |  |                               |  
|S. Rogers        |  | 2018 |  |  |                         | 3,735  |  |                                                  |   | 47,232 |                                                              |  |   | -                             |  |  |       | -       |  |                               |  



21







(13) Eligible employees have the
right to purchase restricted stock with a portion of their annual bonus (up to 20%). Each restricted stock purchase is entitled
to a premium equal to 25% of the number of shares of the purchase, paid on the third anniversary of the purchase, only if the employee
is still employed with the Company.



(14) Represents expenses incurred
in relocating employee.



(15)Represents $20,874 that Mr.
Kennally received during fiscal 2018 as compensation for serving as a non-employee director before being named our chief executive
officer.



(16)Includes $1,107,810
severance payable in fiscal 2019 and 2020 and $2,016,716 related to the fair value of stock awards (163,608 shares)
that were accelerated upon Mr. Guccione’s resignation.



22







2018 GRANTS OF PLAN-BASED AWARDS



The following table discloses information
regarding plan awards made to each of our named executive officers during the year ended June 30, 2018.



|                      |  |            |  | Estimated
    Future Payouts Under Non-
    Equity Incentive Plan Awards (1) |         |  | Estimated
    Future Payouts Under 
    Equity Incentive Plan Awards (2) |   |         | All
    
    Other 
    Stock 
    Awards: 
    Number 
    of 
    Shares 
    of Stock |  |   | All
    Other 
    Option 
    Awards: 
    Number of 
    Securities 
    Underlying |  |  | Exercise
    
    or Base 
    Price of 
    Option |        |  | Grant
    Date 
    Fair Value 
    of Stock 
    and Option | 
|--------------------- |  | ---------- |  | ---------------------------------------------------------------------------- | ------- |  | ------------------------------------------------------------------------ | - | ------- | ---------------------------------------------------------------------------------------- |  | - | ------------------------------------------------------------------------------------- |  |  | --------------------------------------------------- | ------ |  | ------------------------------------------------------------ | 
|Name                  |  | Grant Date |  | Threshold ($)                                                                |         |  | Target ($)                                                               |   |         | Maximum ($)                                                                              |  |   | Threshold (#)                                                                         |  |  | Target (#)                                          |        |  | Maximum (#)                                                  | 
|                      |  |            |  |                                                                              |         |  |                                                                          |   |         |                                                                                          |  |   |                                                                                       |  |  |                                                     |        |  |                                                              | 
|William Kennally, III |  | 10/02/17   |  | $                                                                            | 325,000 |  |                                                                          | $ | 650,000 |                                                                                          |  | $ | 1,300,000                                                                             |  |  |                                                     | 17,500 |  |                                                              | 
|Walter Kaczmarek, III |  | 9/01/17    |  |                                                                              | 146,775 |  |                                                                          |   | 293,550 |                                                                                          |  |   | 587,100                                                                               |  |  |                                                     | 8,300  |  |                                                              | 
|Albert Eilender       |  | 9/01/17    |  |                                                                              | 146,625 |  |                                                                          |   | 293,250 |                                                                                          |  |   | 586,500                                                                               |  |  |                                                     | 14,600 |  |                                                              | 
|Steven Rogers         |  | 9/01/17    |  |                                                                              | 92,700  |  |                                                                          |   | 185,400 |                                                                                          |  |   | 370,800                                                                               |  |  |                                                     | 5,500  |  |                                                              | 
|Salvatore Guccione    |  | 9/01/17    |  |                                                                              | 238,361 |  |                                                                          |   | 476,723 |                                                                                          |  |   | 953,445                                                                               |  |  |                                                     | 15,200 |  |                                                              | 
|Douglas Roth          |  | 9/01/17    |  |                                                                              | 99,555  |  |                                                                          |   | 199,109 |                                                                                          |  |   | 398,218                                                                               |  |  |                                                     | 8,300  |  |                                                              | 
|Edward Borkowski      |  | 2/21/18    |  |                                                                              | 138,000 |  |                                                                          |   | 276,000 |                                                                                          |  |   | 552,000                                                                               |  |  |                                                     | -      |  |                                                              | 





No awards were made to Rebecca Roof, as she is compensated by
AlixPartners and not by the Company.



(1) Actual awards paid for 2018 performance
are included in the Summary Compensation Table under the column Non-Equity Incentive Plan Compensation, while opportunities
for 2018 at threshold, target and maximum are included in the above 2018 Grants of Plan-Based Awards.These amounts were
determined using financial factors related to our company and results obtained with respect to certain individual goals that were
tailored for each named executive officer and approved by our Compensation Committee.



(2) Represents a grant of performance-vested
restricted stock units, which grant could be as much as 175% of the original grant if certain performance criteria, including adjusted
pre-tax income and total shareholder return are met. Performance-vested restricted stock units will cliff vest 100% at the end
of the third year following grant in accordance with the performance metrics set forth in the applicable executive officer’s
performance-vested restricted stock unit grant.



(3) Amounts shown in this column reflect
the aggregate grant date fair value of restricted stock awards, restricted stock units and option awards granted during the year
computed in accordance with generally accepted accounting principles. These awards relate to equity awards granted in connection
with the Company’s long-term incentive compensation program.



23







OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END



The following table discloses information
regarding outstanding equity awards granted or accrued as of June 30, 2018 for each of our named executive officers.



|                      |  | Option Awards                                                               |        |  |                                                                       |  |   |                             |  |   | Stock Awards             | 
|--------------------- |  | --------------------------------------------------------------------------- | ------ |  | --------------------------------------------------------------------- |  | - | --------------------------- |  | - | ------------------------ | 
|Name                  |  | Number of  Securities  Underlying  Unexercised  Options (#)  Exercisable(1) |        |  | Number of Securities Underlying Unexercised Options (#) Unexercisable |  |   | Option  Exercise  Price ($) |  |   | Option  Expiration  Date | 
|William Kennally, III |  |                                                                             | -      |  |                                                                       |  | - |                             |  | $ | -                        | 
|Douglas Roth          |  |                                                                             | 20,000 |  |                                                                       |  | - |                             |  |   | 7.76                     | 
|                      |  |                                                                             | 6,000  |  |                                                                       |  | - |                             |  |   | 6.18                     | 
|Walter Kaczmarek, III |  |                                                                             | -      |  |                                                                       |  | - |                             |  |   | -                        | 
|Albert Eilender       |  |                                                                             | 15,000 |  |                                                                       |  | - |                             |  |   | 6.18                     | 
|Steven S. Rogers      |  |                                                                             | -      |  |                                                                       |  | - |                             |  |   | -                        | 



Neither Mr. Guccione, Mr. Borkowski
nor Ms. Roof held any equity awards as of June 30, 2018.



(1) The stock options vested over three years and have a term of ten years from the date of grant. The restricted stock awards also vest over three years. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the award.



(2) Reflects amounts based on the closing market price of the Company’s common stock of $3.35 per share effective on June 30, 2018.



24







OPTION EXERCISES AND STOCK VESTED



The following table shows information concerning
stock options exercised during fiscal 2018 by the named executive officers and restricted stock held by the named executive officers
that vested during fiscal 2018:



|                      |  | Option Awards                             |        |  | Stock Awards                   |  
|--------------------- |  | ----------------------------------------- | ------ |  | ------------------------------ | -
|Name                  |  | Number of Shares Acquired on Exercise (#) |        |  | Value Realized on Exercise ($) |  
|William Kennally, III |  |                                           | -      |  |                                | $
|                      |  |                                           |        |  |                                |  
|Salvatore Guccione    |  |                                           | 75,500 |  |                                |  
|                      |  |                                           |        |  |                                |  
|Douglas Roth          |  |                                           | -      |  |                                |  
|                      |  |                                           |        |  |                                |  
|Walter Kaczmarek, III |  |                                           | -      |  |                                |  
|                      |  |                                           |        |  |                                |  
|Albert L. Eilender    |  |                                           | 6,199  |  |                                |  
|                      |  |                                           |        |  |                                |  
|Steven S. Rogers      |  |                                           | -      |  |                                |  



Neither Mr. Borkowski nor Ms. Roof exercised any stock options
during fiscal 2018 or held any restricted stock or restricted stock units that vested during fiscal 2018.



NON-QUALIFIED DEFERRED COMPENSATION



The following table shows the Non-Qualified
Deferred Compensation amounts earned by the named executive officers during fiscal 2018:



|Name                  |  | Executive  Contributions  in Last FY($) |        |  | Registrant  Contributions in  Last FY ($) (1) |   |        | Aggregate Earnings in  Last FY ($) |  |   | Aggregate Withdrawals/
Distributions  ($) |  |  | Aggregate  Balance at  Last FYE($)(2) |        
|--------------------- |  | --------------------------------------- | ------ |  | --------------------------------------------- | - | ------ | ---------------------------------- |  | - | ----------------------------------------- |  |  | ------------------------------------- | -------
|William Kennally, III |  | $                                       | -      |  |                                               | $ | 14,283 |                                    |  | $ | -                                         |  |  | $                                     | -      
|Salvatore Guccione    |  |                                         | -      |  |                                               |   | -      |                                    |  |   | 20,749                                    |  |  |                                       | 328,157
|Douglas Roth          |  |                                         | -      |  |                                               |   | -      |                                    |  |   | 16,661                                    |  |  |                                       | -      
|Walter Kaczmarek      |  |                                         | -      |  |                                               |   | 21,737 |                                    |  |   | 336                                       |  |  |                                       | -      
|Albert L. Eilender    |  |                                         | 50,000 |  |                                               |   | 19,867 |                                    |  |   | 99,395                                    |  |  |                                       | -      
|Steven S. Rogers      |  |                                         | 10,000 |  |                                               |   | 17,284 |                                    |  |   | 19,083                                    |  |  |                                       | -      



(1) These amounts are reported in the Summary
Compensation Table.

(2) Registrant contributions for prior
fiscal years were included in the registrant’s Summary Compensation Table for prior fiscal years.



Neither Mr. Borkowski nor Ms. Roof earned any Non-Qualified
Deferred Compensation during fiscal 2018.



25







Deferred Compensation Plan



On March 14, 2005, the Board adopted the
SERP. The SERP is a non-qualified deferred compensation plan intended to provide certain qualified executives with supplemental
benefits beyond the Company’s 401(k) plan, as well as to permit additional deferrals of a portion of their compensation.
Substantially all compensation deferred under the SERP, as well as Company contributions, is held by the Company in a grantor trust,
which is considered an asset of the Company. The assets held by the grantor trust are mutual fund investments owned by the Company.
Effective July 1, 2013, the SERP was frozen and a new plan, entitled “Aceto Corporation 2013 Senior Executive Retirement
Plan” was adopted by the Company’s Board.



POTENTIAL PAYMENTS UPON TERMINATION
OR CHANGE-IN-CONTROL



On February 13, 2015, we entered into revised
change in control agreements with Messrs. Eilender and Rogers. These agreements superseded and replaced in their entirety Change
in Control Agreements entered into with such individuals on July 2, 2012. On October 2, 2017 we entered into a change in control
agreement with Mr. Kennally.  The agreements provide “double trigger” change in control severance protections,
which means no amount will become payable under the agreements unless a “change in control” of Aceto occurs and an
executive’s employment is terminated by Aceto other than for “cause” or by the executive for “good reason”
within a specified period following the change in control.



Each agreement will automatically terminate
if the executive ceases to be an employee of Aceto for any reason prior to the occurrence of a “change in control”
(as defined in each agreement).  In addition, the Company can terminate each agreement on one year’s prior written notice;
provided that, if a “change in control” of the Company occurs while the agreement is in effect, no such termination
notice shall become effective until the second anniversary of the “change in control.”



If, during the two (2) year period following
the occurrence of a “change in control,” an executive’s employment is terminated by the Company other than for
“cause” (as defined in each agreement) or by the executive for “good reason” (as defined in each agreement),
subject to the provisions regarding Sections 280G and 4999 of the Code summarized below, the executive will be entitled to the
following (in lieu of any payments under the Company’s severance policy):



| | ○ | a cash lump sum equal to two (2) times the sum of the executive’s base salary (1.75 times
for Mr. Rogers) and annual performance award for the fiscal year preceding the “change in control,” and
| | - | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | ○ | continued participation in the Company’s group health plan, at the Company’s expense,
for a period of two (2) years.
| | - | --------------------------------------------------------------------------------------------------------------------



To the extent not theretofore already vested,
one hundred percent (100%) of the executive’s then-outstanding and unvested “equity awards” (as defined in each
agreement) will become vested in full. If, however, an outstanding equity award is to vest and/or the amount of the award to vest
is to be determined based on the achievement of performance criteria, then the equity award will vest as to one hundred percent
(100%) of the amount of the equity award assuming the performance criteria had been achieved at target levels for the relevant
performance period(s).



To the extent any amount or benefit to
be provided pursuant to the agreement or otherwise (collectively, the “Payments”) would be treated as an “excess
parachute payment,” as that phrase is defined in Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”),
then the amounts and benefits the executive would otherwise receive shall be either (i) paid or allowed in full; or (ii) reduced
(but not below zero) to the maximum amount which may be paid without causing any Payment to be nondeductible to the Company under
Section 280G of the Code, or subject the executive to an excise tax under Section 4999 of the Code, whichever would result in the
executive’s receipt, on an after-tax basis, of the greatest amount of Payments.



Mr. Eilender is eligible to receive severance
pay and benefits pursuant to the Aceto Severance Policy (the “Severance Policy”) in the event of an involuntarily termination
of his employment. Severance pay may be provided under the Severance Policy, in Aceto’s sole discretion, in an amount up
to twelve (12) weeks of base salary plus two (2) additional weeks for each year of service with Aceto, up to a maximum of fifty-two
(52) weeks of base salary.



26







Effective as of September 27, 2017, we
entered into a letter agreement with Mr. Kennally (the “Kennally Letter Agreement”). If
the Company terminates Mr. Kennally’s employment other than for cause, pursuant to the Kennally Letter Agreement the Company
will be required to continue to pay Mr. Kennally’s base salary, at the rate then in effect, for the fifteen month period
following the date of termination, subject to offset by any amounts earned by Mr. Kennally through other employment or consultancy
during the fifteen month period.



In May 2018, the Company entered into an
enhanced severance protection letter agreement with Mr. Rogers. If, prior to a change in control, Mr. Rogers’ employment
is terminated by the Company without cause (other than due to disability), the Company shall continue to pay Mr. Rogers’
base salary, at the rate then in effect, for the fifteen month period following the date of termination as severance.



The following table shows the estimated
amounts that would have been payable to the named executive officers other than Messrs. Guccione, Roth, Borkowski and Kaczmarek
upon the occurrence of the indicated event, had the applicable event occurred on June 30, 2018. The actual compensation and benefits
these executives would receive at any subsequent date would likely vary from the amounts set forth below as a result of certain
factors, such as a change in any additional benefits the officer may have accrued as of that time under applicable benefit or compensation
plans.



Rebecca Roof is not included in the table
below as the Company pays Ms. Roof’s employer AP Services LLC, for her services and she is not separately compensated by
the Company. Messrs. Guccione, Roth and Borkowski are not included in the table below because they are no longer associated with
the Company and thus are not entitled to any amounts upon the occurrence of the events described in the table below.



|Name                  |  | Event                                                                                      |  | Salary ($) |           |  | Bonus ($) |  |         | Company Automobile ($) |  |  | Company Contributions to Retirement Plans ($) |  |  | Equity Awards ($)(1) |   |  | Healthcare and Life Insurance Benefits
 ($) |  |         | Total ($) | 
|--------------------- |  | ------------------------------------------------------------------------------------------ |  | ---------- | --------- |  | --------- |  | ------- | ---------------------- |  |  | --------------------------------------------- |  |  | -------------------- | - |  | ------------------------------------------- |  | ------- | --------- | 
|                      |  |                                                                                            |  |            |           |  |           |  |         |                        |  |  |                                               |  |  |                      |   |  |                                             |  |         |           | 
|William Kennally, III |  | Termination without cause or resignation for good reason                                   |  |            | 812,500   |  |           |  | -       |                        |  |  | -                                             |  |  |                      | - |  |                                             |  | 79,563  |           | 
|                      |  |                                                                                            |  |            |           |  |           |  |         |                        |  |  |                                               |  |  |                      |   |  |                                             |  |         |           | 
|                      |  | Termination without cause or resignation for good reason following a change in control     |  |            | 1,300,000 |  |           |  | 348,405 |                        |  |  | -                                             |  |  |                      | - |  |                                             |  | 318,250 |           | 
|Albert L. Eilender    |  | Termination without cause or resignation for good reason                                   |  |            | 394,760   |  |           |  | -       |                        |  |  | -                                             |  |  |                      | - |  |                                             |  | 248,165 |           | 
|                      |  |                                                                                            |  |            |           |  |           |  |         |                        |  |  |                                               |  |  |                      |   |  |                                             |  |         |           | 
|                      |  | Termination without cause or resignation for good reason following a
    change in control |  |            | 977,500   |  |           |  | 157,184 |                        |  |  | -                                             |  |  |                      | - |  |                                             |  | 504,835 |           | 
|Steven S. Rogers      |  | Termination without cause or resignation for good reason                                   |  |            | 463,240   |  |           |  | -       |                        |  |  | -                                             |  |  |                      | - |  |                                             |  | 88,832  |           | 
|                      |  |                                                                                            |  |            |           |  |           |  |         |                        |  |  |                                               |  |  |                      |   |  |                                             |  |         |           | 
|                      |  | Termination without cause or resignation for good reason following a change in control     |  |            | 648,537   |  |           |  | 86,954  |                        |  |  | -                                             |  |  |                      | - |  |                                             |  | 188,669 |           | 



(1)     For termination without cause
or resignation for good reason, the above-mentioned executives’ then outstanding and unvested equity awards will vest on
a pro-rata basis based on the termination date. Upon a change in control, 100% of the above-named executives' then-outstanding
and unvested equity awards will become vested in full.



27







COMPENSATION OF DIRECTORS



The fiscal 2018 fees for non-employee directors
are shown in the table below:



|Fee Type                                                                               |  | Value in $ |       
|-------------------------------------------------------------------------------------- |  | ---------- | ------
|Annual Retainer – Cash                                                                 |  | $          | 47,500
|Annual Retainer – Stock (1)                                                            |  |            | 70,000
|Annual Lead Independent Director Fee                                                   |  |            | 17,500
|Annual Retainer for Chairperson:                                                       |  |            |       
|Audit & Risk Committee                                                                 |  |            | 15,000
|Compensation Committee                                                                 |  |            | 12,000
|Nominating & Governance Committee                                                      |  |            | 8,000 
|Board of Director Meeting Fee                                                          |  |            | 1,750 
|Non-Employee Director Meeting Fee (for meetings held solely by Non-Employee Directors) |  |            | 1,500 
|Audit & Risk Committee Meeting Fee                                                     |  |            | 2,250 
|Compensation Committee Meeting Fee                                                     |  |            | 2,000 
|Nominating & Governance Committee Meeting Fee                                          |  |            | 1,250 



| | (1) | Awarded in December 2017 following the annual meeting of
shareholders
| | --- | ---------------------------------------------------------------------

| | * | - per meeting attended
| | - | ----------------------



Employees of the Company who are also directors
do not receive any separate fees for acting as directors.



The following table sets forth the compensation
of our non-employee directors for the fiscal year ended June 30, 2018.



|DIRECTOR COMPENSATION
|---------------------
|                     
|Name                 
|                     
|William N. Britton   
|                     
|Natasha Giordano     
|                     
|Alan G. Levin        
|                     
|Dr. Daniel B. Yarosh 



Directors also receive reimbursement for
expenses incurred in connection with meeting attendance.



(1) Includes
payments made in fiscal 2018 for attendance at certain meetings held at the end of fiscal 2017 and does not include payments for
attendance at certain meetings held at the end of fiscal 2018 for which payments will be made in fiscal 2019.In addition,
fees include ad-hoc committee service as needed.



(2)Amounts shown in this column reflect the aggregate grant date
fair value of restricted stock awards granted during the year computed in accordance with generally accepted accounting principles.
There were no option grants awarded to directors in fiscal 2018.



28







The following is a list of the outstanding
options and restricted stock awards held by each of our non-employee directors as of June 30, 2018:



|                     |  | Option Awards (#) |   |  | Stock Awards (#) | 
|-------------------- |  | ----------------- | - |  | ---------------- | 
|                     |  |                   |   |  |                  | 
|William N. Britton   |  |                   | - |  |                  | 
|Natasha Giordano     |  |                   | - |  |                  | 
|Alan G. Levin        |  |                   | - |  |                  | 
|Dr. Daniel B. Yarosh |  |                   | - |  |                  | 



Compensation Committee Interlocks and
Insider Participation



None of the independent directors responsible
for compensation matters has ever served as an officer or employee of the Company or any of our subsidiaries. During the last fiscal
year, none of our senior executives served on the Board or committee of any other entity whose officers served either on our Board
or Compensation Committee. During the last fiscal year, none of the members of the Compensation Committee had a direct or indirect
material interest in any transaction in which the Company was a participant and the amount involved exceeded $120,000.



29







Item 12. SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS



The following table states certain information
with respect to our equity compensation plans at June 30, 2018:



|Plan category                                              |  | Number of securities to be issued upon exercise  of outstanding options |         |  | Weighted-average exercise price of outstanding options |   |      | Number of securities remaining available for future issuance under  equity compensation plans | 
|---------------------------------------------------------- |  | ----------------------------------------------------------------------- | ------- |  | ------------------------------------------------------ | - | ---- | --------------------------------------------------------------------------------------------- | 
|                                                           |  |                                                                         |         |  |                                                        |   |      |                                                                                               | 
|Equity compensation plans approved by security holders     |  |                                                                         | 129,000 |  |                                                        | $ | 7.44 |                                                                                               | 
|                                                           |  |                                                                         |         |  |                                                        |   |      |                                                                                               | 
|Equity compensation plans not approved by security holders |  |                                                                         | -       |  |                                                        |   | -    |                                                                                               | 
|Total                                                      |  |                                                                         | 129,000 |  |                                                        | $ | 7.44 |                                                                                               | 



The following table sets
forth, as of October 15, 2018, the number and percentage of shares of the Company’s outstanding common stock owned by each
named executive officer (except as otherwise set forth below), each director and each person that, to the best of the Company’s
knowledge, owns more than 5% of the Company’s issued and outstanding common stock, and all executive officers and directors
as a group. Unless indicated otherwise, the information in the table is as of October 15, 2018 and the business address of each
person is c/o Aceto Corporation, 4 Tri Harbor Court, Port Washington, New York 11050. Information in the table below is not reflected
with respect to Salvatore Guccione, Edward Borkowski or Douglas Roth, as they are no longer associated with Aceto and are no longer
subject to applicable beneficial ownership reporting requirements.



|Name and Address of Beneficial Owner                                  |  | Number of Shares Beneficially Owned (excluding stock options and 
restricted stock 
units) (#) (1) |           |  | Exercisable Stock Options and 
Restricted Stock 
Units (#) (2) |  |        | Total Beneficial 
Ownership (#) |  |  | Percent % (3) | 
|--------------------------------------------------------------------- |  | -------------------------------------------------------------------------------------------------- | --------- |  | -------------------------------------------------------------- |  | ------ | ------------------------------- |  |  | ------------- | 
|                                                                      |  |                                                                                                    |           |  |                                                                |  |        |                                 |  |  |               | 
|Directors and Officers:                                               |  |                                                                                                    |           |  |                                                                |  |        |                                 |  |  |               | 
|William C. Kennally, III                                              |  |                                                                                                    | 64,334    |  |                                                                |  | -      |                                 |  |  | 64,334        | 
|Rebecca Roof                                                          |  |                                                                                                    | -         |  |                                                                |  | -      |                                 |  |  | -             | 
|Walter Kaczmarek, III                                                 |  |                                                                                                    | 56,782    |  |                                                                |  | -      |                                 |  |  | 56,782        | 
|Albert L. Eilender (4)                                                |  |                                                                                                    | 297,313   |  |                                                                |  | 15,000 |                                 |  |  | 312,313       | 
|Vimal Kavuru (5)                                                      |  |                                                                                                    | -         |  |                                                                |  | -      |                                 |  |  | -             | 
|Steven S. Rogers                                                      |  |                                                                                                    | 34,500    |  |                                                                |  | -      |                                 |  |  | 34,500        | 
|William N. Britton                                                    |  |                                                                                                    | 50,771    |  |                                                                |  | -      |                                 |  |  | 50,771        | 
|Natasha Giordano                                                      |  |                                                                                                    | 20,972    |  |                                                                |  | -      |                                 |  |  | 20,972        | 
|Alan G. Levin                                                         |  |                                                                                                    | 18,248    |  |                                                                |  | -      |                                 |  |  | 18,248        | 
|Daniel B. Yarosh                                                      |  |                                                                                                    | 14,916    |  |                                                                |  | -      |                                 |  |  | 14,916        | 
|                                                                      |  |                                                                                                    |           |  |                                                                |  |        |                                 |  |  |               | 
|Five percent shareholders:                                            |  |                                                                                                    |           |  |                                                                |  |        |                                 |  |  |               | 
|BlackRock Inc. (6) 55 East 52nd Street  New York, NY 10022            |  |                                                                                                    | 2,882,902 |  |                                                                |  | -      |                                 |  |  | 2,882,902     | 
|                                                                      |  |                                                                                                    |           |  |                                                                |  |        |                                 |  |  |               | 
|Dimensional Fund Advisors LP (6) 6300 Bee Cave Road Austin, TX  78746 |  |                                                                                                    | 2,539,225 |  |                                                                |  | -      |                                 |  |  | 2,539,225     | 



30









|Name and Address of Beneficial Owner                                      |  | Number of Shares
        Beneficially
        Owned (excluding
        stock options and
        restricted stock
        units) (#) (1) |           |  | Exercisable Stock
        Options and
        Restricted Stock
        Units (#) (2) |  |        | Total BeneficialOwnership (#) |  |  | Percent % (3) | 
|------------------------------------------------------------------------- |  | ---------------------------------------------------------------------------------------------------------------------------------------- | --------- |  | ------------------------------------------------------------------------------------ |  | ------ | ----------------------------- |  |  | ------------- | 
|                                                                          |  |                                                                                                                                          |           |  |                                                                                      |  |        |                               |  |  |               | 
|Vanguard Group, Inc.(6)PO Box 2600Valley Forge, PA 19482                  |  |                                                                                                                                          | 2,437,675 |  |                                                                                      |  | -      |                               |  |  | 2,437,675     | 
|                                                                          |  |                                                                                                                                          |           |  |                                                                                      |  |        |                               |  |  |               | 
|Thomas A. Satterfield, Jr. (7)2609 Caldwell Mill LaneBirmingham, AL 35243 |  |                                                                                                                                          | 1,639,000 |  |                                                                                      |  | -      |                               |  |  | 1,639,000     | 
|                                                                          |  |                                                                                                                                          |           |  |                                                                                      |  |        |                               |  |  |               | 
|All executive officers and directors as a group (13 persons)              |  |                                                                                                                                          | 688,120   |  |                                                                                      |  | 35,000 |                               |  |  | 723,120       | 








* Less than 1%.



| | (1) | Unless otherwise indicated, each person has, or shares with his or her spouse, sole voting and
dispositive power over the shares shown as owned by him or her.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | For purposes of the table, a person is deemed to have “beneficial ownership” of
                                                                 any shares which such person has the right to acquire within 60 days after October 15, 2018. Any share which such person has
                                                                 the right to acquire within those 60 days is deemed to be outstanding for the purpose of computing the percentage ownership
                                                                 of such person, but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other
                                                                 person.
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (3) | Based on 30,800,574 shares issued and outstanding as of October 15, 2018.
| | --- | -------------------------------------------------------------------------



| | (4) | Includes 6,950 shares owned indirectly by Mr. Eilender through a trust.
| | --- | -----------------------------------------------------------------------



| | (5) | Pursuant to the product purchase agreement that Aceto entered into to acquire certain of the products
and related assets of Citron and Lucid (the “Product Purchase Agreement”), and as one of the elements of the consideration
payable thereunder, Aceto is obligated to issue 5,121,951 shares of Common Stock to the sellers thereunder (the “Sellers”).
Aceto is required to issue 75% of those shares to the Sellers in December 2019 (on the third anniversary of the closing of the
transaction) and 25% of those shares one year later, subject in all cases to certain indemnification and set-off provisions set
forth in the Product Purchase Agreement. Such shares are also subject to voting and transfer restrictions previously disclosed
by us. Mr. Kavuru is a principal equity owner and executive officer of entities that own, directly or indirectly, the Sellers.
Inasmuch as such 5,121,951 shares have not been issued as yet and are not issuable within 60 days after October 15, 2018, such
shares have not been included in the table set forth above.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (6) | Based on information filed on Schedule 13F with the Securities and Exchange Commission as of October
15, 2018.
| | --- | --------------------------------------------------------------------------------------------------------------



| | (7) | Based on information filed on Schedule 13G with the Securities and Exchange Commission on October
11, 2018.
| | --- | -----------------------------------------------------------------------------------------------------------



31







Item 13. CERTAIN RELATIONSHIPS AND
RELATED TRANSACTIONS



During fiscal 2018, 2017 and 2016,
the Company purchased inventory from a corporate joint venture in the amount of $3,556,000, $3,236,000 and $2,831,000,
respectively.



Rising Health and Acetris Health incurred
costs of $2,636,000 and $305,000 in fiscal 2018 and $1,865,000 and $165,000 in fiscal 2017, respectively, related to consulting
services provided by former Citron and Lucid employees, in connection with a transition services agreement entered into at the
time of the Company’s 2016 product purchase agreement. Citron and Lucid are affiliates of Vimal Kavuru, a member of the
Company’s Board of Directors.



In October 2017, Rising commenced leasing approximately 125,000 gross square feet of warehouse
space in Somerset, New Jersey. This building is owned by an affiliate of Mr. Kavuru. The Company incurred $569,000 of rent expense
related to this lease during fiscal 2018.



During fiscal 2018, Rising Health purchased
inventory in the amount of $290,000 from Casper Pharma, LLC, which is an affiliate of Mr. Kavuru.



On November 2, 2016, the Company, Citron
and Cronus Research Labs Private Limited, a research and development company headquartered
in India that is affiliated with Vimal Kavuru (“Cronus”), entered into two amended and restated joint development
agreements pursuant to which Cronus has been engaged to develop a portfolio of nine pipeline products (“Development Agreement
I”) and certain other products (“Development Agreement II” and together with Development Agreement I, the “Development
Agreements”) on behalf of Citron. Under the terms of Development Agreement I, Cronus has agreed to pay the first $3,500,000
of the development costs incurred after December 21, 2016, and 50% of any development costs incurred above that threshold in exchange
for obtaining reimbursement for its costs funded out of the profits earned, if any, from the pipeline products that are commercially
launched, and a specified portion of the profits from those products thereafter. Under the terms of Development Agreement II, Cronus
has agreed to pay the development costs for the products covered thereby in exchange for obtaining reimbursement for its costs
funded out of the profits earned, if any, from such products that are commercially launched (subject to a $1,445,000 maximum),
and a specified portion of the profits from those products thereafter.



Mr. Kavuru was not a member of the Company’s
Board at the time that the above-mentioned transition services agreement, lease or Development Agreements were executed.



Pursuant to its charter, the Company’s
Audit & Risk Committee shall review on an on-going basis for potential conflicts of interest, and approve if appropriate, all
“Related Party Transactions” of the Company as required by the applicable NASDAQ listing rule. For purposes of the
Audit & Risk Committee charter, “Related Party Transactions” shall mean those transactions required to be disclosed
pursuant to SEC Regulation S-K, Item 404.



Item 14. PRINCIPAL ACCOUNTING FEES AND
SERVICES



The aggregate fees for professional services
rendered by BDO USA, LLP for the years ended June 30, 2018 and 2017 were:



|                   |  | Fiscal 2018 |           |  | Fiscal 2017 |  
|------------------ |  | ----------- | --------- |  | ----------- | -
|                   |  |             |           |  |             |  
|Audit fees         |  | $           | 2,028,000 |  |             | $
|Audit related fees |  |             | -         |  |             |  
|Tax fees           |  |             | 229,000   |  |             |  
|                   |  |             |           |  |             |  
|Total fees         |  | $           | 2,257,000 |  |             | $



Audit fees are fees for the audit of the
Company’s annual financial statements included on Form 10-K, including the audits of internal control over financial reporting,
reviews of the quarterly financial statements, statutory audits and assistance with and review of documents filed with the SEC.



Audit related fees consisted of fees for
due diligence and accounting consultations in connection with acquisitions.



32







Tax fees are fees for tax services, including
tax compliance, tax advice and planning.



The Audit & Risk Committee reviewed
and approved in advance in accordance with the Company’s Audit & Risk Committee Pre-Approval Policy all proposals and
fees for any work to be performed by BDO USA, LLP.



Item
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES



The following documents are filed as part
of this Report:



| | (a) | The financial statements listed in the Index to Consolidated
Financial Statements are filed as part of the Annual Report on Form 10-K. All financial statement schedules have been included
in the Consolidated Financial Statements or Notes thereto.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (b) | Exhibits
| | --- | --------





|Exhibit Number |  | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 
|-------------- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | 
|               |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|2.1            |  | Membership Interest Purchase Agreement, dated March 26, 2014, by and among PACK Pharmaceuticals, LLC, the Aschenbrand and O’Brien Family Trust, dated March 2001, Bryan Aschenbrand – Trustee, Dushyant Chipalkattty, Chris Dungan, Aceto Corporation, Rising Pharmaceuticals, Inc. and Chris Dungan, solely in his capacity as the representative of the Sellers (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K dated March 28, 2014).                                                                                                                                     
|               |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|2.2            |  | Form of Lock-up Agreement (incorporated by reference to Exhibit 2.2 to our Current Report on Form 8-K dated March 28, 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|               |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|2.3            |  | Product Purchase Agreement, by and among Aceto Corporation,   Cedar Pharma LLC (f/k/a Citron Pharma LLC and referred to herein as “Citron”), Aster Pharma LLC (f/k/a Lucid Pharma LLC and together with Citron, the “Sellers”), the direct and indirect equity owners of the Sellers (the Members), Rising Health, LLC (“Purchaser I”),  Acetris Health, LLC (together with Purchaser I, the “Purchasers”) and an agent for the Sellers and the Members (the “Agent”), dated as of November 2, 2016  (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K dated November 2, 2016).
|               |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|2.4            |  | Amendment No. 1 to the Product Purchase Agreement, by and among the Purchasers and the Agent, dated as of December 2, 2016 (incorporated by reference to Exhibit 2.2 to our Current Report on Form 8-K dated December 21, 2016).                                                                                                                                                                                                                                                                                                                                                                         
|               |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|2.5            |  | Transaction Agreement Amendment and Waiver, dated as of December 21, 2016, by and among the Purchasers, the Agent, Rising Pharmaceuticals, Inc. and Vimal Kavuru (incorporated by reference to Exhibit 2.3 to our Current Report on Form 8-K dated December 21, 2016).                                                                                                                                                                                                                                                                                                                                   
|               |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|3.1            |  | Amended and Restated Certificate of Incorporation filed with the Department of State of the State of New York on November 9, 2015 (incorporated by reference to Exhibit 3.1 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2016).                                                                                                                                                                                                                                                                                                                                     
|               |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|3.2            |  | Amendment to the Amended and Restated Certificate of Incorporation filed with the Department of State of the State of New York on December 15, 2015 (incorporated by reference to Exhibit 3.2 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2016).                                                                                                                                                                                                                                                                                                                   
|               |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|3.3            |  | Amendment to the Amended and Restated Certificate of Incorporation filed with the Department of State of the State of New York on December 9, 2016 (incorporated by reference to Exhibit 3.3 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2016).                                                                                                                                                                                                                                                                                                                    
|               |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|3.4            |  | Aceto Corporation By-Laws, amended July 28, 2014 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K dated July 31, 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                       





33







|4.1   |  | Indenture, dated November 16, 2015 between Aceto Corporation and Citibank, N.A. (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K dated November 16, 2015).                                                                                                                                                                                                                  
|----- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|4.2   |  | Form of Global 2.00% Convertible Senior Note due 2020 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K dated November 16, 2015).                                                                                                                                                                                                                                            
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.1  |  | Aceto Corporation 401(k) Retirement Plan, as amended and restated as of July 1, 2002 (incorporated by reference to Exhibit 10.1 to the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2004 (File Number: 000-04217, Film Number: 041025874)).                                                                                                                                 
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.2  |  | Supplemental Executive Retirement Plan, as amended and restated effective June 30, 2004 and frozen as of December 31, 2004 (incorporated by reference to Exhibit 10.2 to the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2004 (File Number: 000-04217, Film Number: 041025874)).                                                                                           
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.3  |  | 1998 Omnibus Equity Award Plan (incorporated by reference to Exhibit 10(v) (c) to the Company’s annual report on Form 10-K for the fiscal year ended June 30, 1999 (File Number: 000-04217, Film Number: 99718824)).                                                                                                                                                                                   
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.4  |  | Supplemental Executive Deferred Compensation Plan, effective March 14, 2005 (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2005 (File Number: 000-04217, Film Number: 05688328)).                                                                                                               
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.5  |  | 2007 Long-Term Performance Incentive Plan (incorporated by reference to Exhibit 4.1 to Registration Statement No. 333-149586 on Form S-8).                                                                                                                                                                                                                                                             
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.6  |  | Supplemental Executive Deferred Compensation Plan, amended and restated effective December 8, 2008 (incorporated by reference to Exhibit 10.22 to the Company’s annual report on Form 10-K for the year ended June 30, 2009).                                                                                                                                                                          
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.7  |  | Purchase and Sale Agreement among Schweizerhall Holding AG, Chemische Fabrik Schweizerhall, Schweizerhall, Inc., Aceto Corporation and Aceto Holding B.V., I.O., dated as of January 28, 2001 (incorporated by reference to Exhibit 2.1 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on April 4, 2001 (File Number: 000-04217, Film Number: 1595350)).
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.8  |  | Form of purchase agreement between Shanghai Zhongjin Real Estate Development Company Limited and Aceto (Hong Kong) Limited, dated November 10, 2004 (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2004 (File Number: 000-04217, Film Number: 05588472)).                                                                
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.9  |  | Guarantee by Aceto Corporation and subsidiaries in favor of Deutsche Bank, AG, dated March 22, 2001 (incorporated by reference to Exhibit 10.13 to the Company’s annual report on Form 10-K for the year ended June 30, 2001 (File Number: 000-04217, Film Number: 1748270)).                                                                                                                          
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.10 |  | Reaffirmation Agreement by Aceto Corporation, Aceto Agricultural Chemicals Corporation, CDC Products Corporation, Aceto Pharma Corp., Aceto Realty LLC, Acci Realty Corp. and Arsynco Inc., dated as of April 23, 2010 (incorporated by reference to Exhibit 10.3 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on April 28, 2010).                    
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.11 |  | Aceto Corporation 2010 Equity Participation Plan (incorporated by reference to Appendix A to our Definitive Proxy Statement on Schedule 14A filed on October 13, 2010).                                                                                                                                                                                                                                
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.12 |  | Aceto Corporation Severance Policy (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated January 17, 2012).                                                                                                                                                                                                                                                               
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                        
|10.13 |  | Aceto Corporation Executive Performance Award Plan (incorporated by reference to Appendix A to our Definitive Proxy Statement on Schedule 14A filed on October 18, 2012).                                                                                                                                                                                                                              





34







|10.14 |  | Amended and Restated Aceto Corporation 2010 Equity Participation Plan (incorporated by reference to Appendix B to our Definitive Proxy Statement on Schedule 14A filed on October 18, 2012).                                                                                                         
|----- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|      |  |                                                                                                                                                                                                                                                                                                      
|10.15 |  | Enhanced Severance Protection Letter Agreement, dated April 3, 2013 between Aceto Corporation and Douglas Roth (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated April 5, 2013).                                                                                    
|      |  |                                                                                                                                                                                                                                                                                                      
|10.16 |  | Aceto Corporation 2013 Senior Executive Retirement Plan (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2013).                                                                                                         
|      |  |                                                                                                                                                                                                                                                                                                      
|10.17 |  | Note Modification Agreement, dated October 21, 2013, between Aceto Realty LLC and JPMorgan Chase Bank, N.A. (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2013).                                                      
|      |  |                                                                                                                                                                                                                                                                                                      
|10.18 |  | Amendment No. 1, dated as of December 26, 2013 to the Change in Control Agreement, dated as of July 2, 2012, by and between the Company and Salvatore J. Guccione (incorporated by reference to Exhibit 10.2 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2013).
|      |  |                                                                                                                                                                                                                                                                                                      
|10.19 |  | Commitment Letter dated March 26, 2014, by and among, Aceto Corporation and the Lead Arrangers and Commitment Lenders (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated March 28, 2014).                                                                            
|      |  |                                                                                                                                                                                                                                                                                                      
|10.20 |  | Credit Agreement, dated as of April 30, 2014, by and among Aceto Corporation, JPMorgan Chase Bank, N.A. as Administrative Agent, Wells Fargo, as Syndication Agent, and the Lenders (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated May 2, 2014).                 
|      |  |                                                                                                                                                                                                                                                                                                      
|10.21 |  | Employment Agreement, effective as of January 1, 2015, between Aceto Corporation and Salvatore Guccione (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated December 18, 2014).                                                                                       
|      |  |                                                                                                                                                                                                                                                                                                      
|10.22 |  | Change in Control Agreement by and between Aceto Corporation and Terry Kippley, dated as of November 5, 2014 (incorporated by reference to Exhibit 10.2 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2014).                                                     
|      |  |                                                                                                                                                                                                                                                                                                      
|10.23 |  | Change in Control Agreement by and between Aceto Corporation and Salvatore Guccione (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated February 18, 2015).                                                                                                           
|      |  |                                                                                                                                                                                                                                                                                                      
|10.24 |  | Change in Control Agreement by and between Aceto Corporation and Albert L. Eilender (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated February 18, 2015).                                                                                                           
|      |  |                                                                                                                                                                                                                                                                                                      
|10.25 |  | Change in Control Agreement by and between Aceto Corporation and Douglas Roth (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated February 18, 2015).                                                                                                                 
|      |  |                                                                                                                                                                                                                                                                                                      
|10.26 |  | Change in Control Agreement by and between Aceto Corporation and Frank DeBenedittis (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated February 18, 2015).                                                                                                           
|      |  |                                                                                                                                                                                                                                                                                                      
|10.27 |  | Change in Control Agreement by and between Aceto Corporation and Satish Srinivasan (incorporated by reference to Exhibit 10.5 to our Current Report on Form 8-K dated February 18, 2015).                                                                                                            
|      |  |                                                                                                                                                                                                                                                                                                      
|10.28 |  | Change in Control Agreement by and between Aceto Corporation and Charles J. Alaimo, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.6 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).                                                   
|      |  |                                                                                                                                                                                                                                                                                                      
|10.29 |  | Change in Control Agreement by and between Aceto Corporation and Raymond B. Bartone, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.7 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).                                                  





35







|10.30 |  | Change in Control Agreement by and between Aceto Corporation and Terry Kippley, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.8 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).                                                                                                                                                                    
|----- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.31 |  | Change in Control Agreement by and between Aceto Corporation and Steven S. Rogers, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.10 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).                                                                                                                                                                
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.32 |  | Change in Control Agreement by and between Aceto Corporation and Nicholas I. Shackley, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.11 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).                                                                                                                                                            
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.33 |  | Amendment No. 1, dated as of June 25, 2015, to the Credit Agreement, dated as of April 30, 2014, by and among Aceto Corporation, JPMorgan Chase Bank, N.A. as Administrative Agent and the Lenders (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated June 25, 2015).                                                                                                             
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.34 |  | Aceto Corporation 2015 Equity Participation Plan (incorporated by reference to Appendix B to our Definitive Proxy Statement on Schedule 14A filed on October 26, 2015).                                                                                                                                                                                                                                           
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.35 |  | Amended and Restated Credit Agreement, dated as of October 28, 2015, by and among Aceto Corporation, the other loan parties thereto, JPMorgan Chase Bank N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated October 28, 2015).                         
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.36 |  | Purchase Agreement, dated November 10, 2015, by and among Aceto Corporation and Wells Fargo Securities, LLC and J.P. Morgan Securities LLC, as representatives of the initial purchasers named therein (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated November 12, 2015).                                                                                                     
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.37 |  | Convertible Note Hedge Confirmation, dated November 10, 2015, between Aceto Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated November 12, 2015).                                                                                                                                                                         
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.38 |  | Convertible Note Hedge Confirmation, dated November 10, 2015, between Aceto Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated November 12, 2015).                                                                                                                                                                      
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.39 |  | Warrant Confirmation, dated November 10, 2015, between ACETO Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated November 12, 2015).                                                                                                                                                                                        
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.40 |  | Warrant Confirmation, dated November 10, 2015, between ACETO Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.5 to our Current Report on Form 8-K dated November 12, 2015).                                                                                                                                                                                     
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.41 |  | Amendment No. 1 to the Amended and Restated Credit Agreement, dated as of October 28, 2015, by and among Aceto Corporation, the other loan parties thereto, JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.6 to our Current Report on Form 8-K dated November 12, 2015).
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.42 |  | Additional Convertible Note Hedge Confirmation, dated November 18, 2015, between Aceto Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated November 23, 2015).                                                                                                                                                              
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                   
|10.43 |  | Additional Convertible Note Hedge Confirmation, dated November 18, 2015, between Aceto Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated November 23, 2015).                                                                                                                                                           





36







|10.44 |  | Additional Warrant Confirmation, dated November 18, 2015, between Aceto Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated November 23, 2015).                                                                                                                                                                                                           
|----- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.45 |  | Additional Warrant Confirmation, dated November 18, 2015, between Aceto Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated November 23, 2015).                                                                                                                                                                                                        
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.46 |  | Letter Agreement between Aceto Corporation and Walter J. Kaczmarek III (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated July 18, 2016).                                                                                                                                                                                                                                                                       
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.47 |  | Change in Control Agreement by and between Aceto Corporation and Walter J. Kaczmarek III (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated July 18, 2016).                                                                                                                                                                                                                                                     
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.48 |  | Amendment No. 2 to the Amended and Restated Credit Agreement, dated as of October 28, 2015, by and among Aceto Corporation, the other loan parties thereto, JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2016).
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.49 |  | Form of Restricted Stock Award Agreement (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated July 28, 2016).                                                                                                                                                                                                                                                                                                     
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.50 |  | Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated July 28, 2016).                                                                                                                                                                                                                                                                                                
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.51 |  | Second Amended and Restated Credit Agreement, dated as of December 21, 2016, by and among the Company, the other loan parties thereto, JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated December 21, 2016).                                                   
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.52 |  | Stockholders’ Rights Agreement, by and among the Company and the Sellers, dated as of November 2, 2016 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated November 2, 2016).                                                                                                                                                                                                                                    
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.53 |  | Voting Agreement, by and among the Company, the Sellers and the Members, dated as of November 2, 2016 (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated November 2, 2016).                                                                                                                                                                                                                                     
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.54 |  | Employment Agreement, by and between Rising and Vimal Kavuru, dated as of November 2, 2016 (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated November 2, 2016).                                                                                                                                                                                                                                                
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.55 |  | Separation Agreement by and between Aceto Corporation and Salvatore Guccione (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated September 27, 2017).                                                                                                                                                                                                                                                            
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.56 |  | Employment Letter Agreement by and between Aceto Corporation and William C. Kennally, III (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K/A dated October 17, 2017).                                                                                                                                                                                                                                               
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.57 |  | Change in Control Agreement by and between Aceto Corporation and William C. Kennally, III (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K/A dated October 17, 2017).                                                                                                                                                                                                                                               
|      |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|10.58 |  | First Amendment to Second Amended and Restated Credit Agreement, dated as of December 13, 2017 by and among the Company, certain other loan parties party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated December 18, 2017).                                                                        





37







|10.59     |  | Agreement between Aceto Corporation and Edward J. Borkowski (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated February 16, 2018).                                                         
|--------- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|          |  |                                                                                                                                                                                                                            
|10.60     |  | Change in Control Agreement between Aceto Corporation and Edward J. Borkowski (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated February 16, 2018).                                       
|          |  |                                                                                                                                                                                                                            
|10.61     |  | Second Amendment and Waiver to Second Amended and Restated Credit Agreement, dated as of May 3, 2018  (incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q dated May 7, 2018).                  
|          |  |                                                                                                                                                                                                                            
|10.62     |  | Third Amendment and Limited Waiver to Second Amended and Restated Credit Agreement, dated as of September 11, 2018  (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated September 12, 2018).
|          |  |                                                                                                                                                                                                                            
|10.63*    |  | Severance Agreement between Aceto Corporation and Steven S. Rogers, dated as of May 21, 2018.                                                                                                                              
|          |  |                                                                                                                                                                                                                            
|10.64*    |  | Retention Bonus Agreement between Aceto Corporation and Steven S. Rogers, dated as of May 21, 2018.                                                                                                                        
|          |  |                                                                                                                                                                                                                            
|10.65*    |  | Form of Retention Bonus Agreement.                                                                                                                                                                                         
|          |  |                                                                                                                                                                                                                            
|21**      |  | Subsidiaries of the Company.                                                                                                                                                                                               
|          |  |                                                                                                                                                                                                                            
|23**      |  | Consent of BDO USA, LLP.                                                                                                                                                                                                   
|          |  |                                                                                                                                                                                                                            
|31.1*     |  | Certifications of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                   
|          |  |                                                                                                                                                                                                                            
|31.2*     |  | Certifications of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                   
|          |  |                                                                                                                                                                                                                            
|32.1**    |  | Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                         
|          |  |                                                                                                                                                                                                                            
|32.2**    |  | Certifications of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                         
|          |  |                                                                                                                                                                                                                            
|101.INS** |  | XBRL Instance Document                                                                                                                                                                                                     
|          |  |                                                                                                                                                                                                                            
|101.SCH** |  | XBRL Taxonomy Extension Schema Document                                                                                                                                                                                    
|          |  |                                                                                                                                                                                                                            
|101.CAL** |  | XBRL Taxonomy Extension Calculation Linkbase Document                                                                                                                                                                      
|          |  |                                                                                                                                                                                                                            
|101.DEF** |  | XBRL Taxonomy Extension Definition Linkbase Document                                                                                                                                                                       
|          |  |                                                                                                                                                                                                                            
|101.LAB** |  | XBRL Taxonomy Extension Label Linkbase Document                                                                                                                                                                            
|          |  |                                                                                                                                                                                                                            
|101.PRE** |  | XBRL Taxonomy Extension Presentation Linkbase Document                                                                                                                                                                     



* Filed herewith

** Previously filed.



38







SIGNATURES



Pursuant to the requirements of Section
13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



| | ACETO CORPORATION                                              
| | ---------------------------------------------------------------
| |                                                                
| | By                                                             
| | William C. Kennally, III, President and
Chief Executive Officer
| | (Principal Executive Officer)                                  
| |                                                                
| | Date:   October 25, 2018                                       



Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities
and on the dates indicated.



|Signatures                  |  | Title                                            |  | Date    
|--------------------------- |  | ------------------------------------------------ |  | --------
|                            |  |                                                  |  |         
|/s/William C. Kennally, III |  | President and Chief Executive Officer            |  | 10-25-18
|William C. Kennally, III    |  | (Principal Executive Officer)                    |  |         
|                            |  |                                                  |  |         
|/s/Rebecca Roof             |  | Chief Financial Officer                          |  | 10-25-18
|Rebecca Roof                |  | (Principal Financial Officer)                    |  |         
|                            |  |                                                  |  |         
|/s/ Frances P. Scally       |  | Senior Vice President & Chief Accounting Officer |  | 10-25-18
|Frances P. Scally           |  | (Principal Accounting Officer)                   |  |         
|                            |  |                                                  |  |         
|/s/ Alan G. Levin           |  | Chairman                                         |  | 10-25-18
|Alan G. Levin               |  |                                                  |  |         
|                            |  |                                                  |  |         
|/s/ Albert L. Eilender      |  | Director                                         |  | 10-25-18
|Albert L. Eilender          |  |                                                  |  |         
|                            |  |                                                  |  |         
|/s/ Vimal Kavuru            |  | Director                                         |  | 10-25-18
|Vimal Kavuru                |  |                                                  |  |         
|                            |  |                                                  |  |         
|/s/ William N. Britton      |  | Director                                         |  | 10-25-18
|William Britton             |  |                                                  |  |         
|                            |  |                                                  |  |         
|/s/ Natasha Giordano        |  | Director                                         |  | 10-25-18
|Natasha Giordano            |  |                                                  |  |         
|                            |  |                                                  |  |         
|/s/ Daniel Yarosh           |  | Director                                         |  | 10-25-18
|Daniel Yarosh               |  |                                                  |  |         



39







PART IV



EXHIBIT INDEX



|Exhibit
    Number |  | Description                                                                                                                                             | 
|------------------ |  | ------------------------------------------------------------------------------------------------------------------------------------------------------- | 
|                   |  |                                                                                                                                                        
|10.63*             |  | Severance Agreement between Aceto Corporation and Steven S, Rogers, dated as of May 21, 2018.                                                          
|                   |  |                                                                                                                                                        
|10.64*             |  | Retention Bonus Agreement between Aceto Corporation and Steven S, Rogers, dated as of May 21, 2018.                                                    
|                   |  |                                                                                                                                                        
|10.65*             |  | Form of Retention Bonus Agreement.                                                                                                                     
|                   |  |                                                                                                                                                        
|31.1*              |  | Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|                   |  |                                                                                                                                                        
|31.2*              |  | Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.



* Filed herewith.



40